US20040220119A1 - Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care - Google Patents
Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care Download PDFInfo
- Publication number
- US20040220119A1 US20040220119A1 US10/817,330 US81733004A US2004220119A1 US 20040220119 A1 US20040220119 A1 US 20040220119A1 US 81733004 A US81733004 A US 81733004A US 2004220119 A1 US2004220119 A1 US 2004220119A1
- Authority
- US
- United States
- Prior art keywords
- free
- cox
- group
- skin
- flavan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 B.C.[1*]C1=C2C(=O)C([5*])=C(C3=CC=CC=C3)OC2=C([4*])C([3*])=C1[2*] Chemical compound B.C.[1*]C1=C2C(=O)C([5*])=C(C3=CC=CC=C3)OC2=C([4*])C([3*])=C1[2*] 0.000 description 10
- HDPBUCGAWFIVEZ-UHFFFAOYSA-N B.C.O=C1C=C(C2=CC=CC=C2)OC2=CC=CC=C12 Chemical compound B.C.O=C1C=C(C2=CC=CC=C2)OC2=CC=CC=C12 HDPBUCGAWFIVEZ-UHFFFAOYSA-N 0.000 description 1
- ZIFMTQBHOSETDO-UHFFFAOYSA-N CC1=CC=C(C2OC3=CC(O)=CC(O)=C3CC2O)C=C1O Chemical compound CC1=CC=C(C2OC3=CC(O)=CC(O)=C3CC2O)C=C1O ZIFMTQBHOSETDO-UHFFFAOYSA-N 0.000 description 1
- OAZFKEIJWMNWND-UHFFFAOYSA-N Nc(c(C1=O)c(c(N)c2N)OC(c3ccccc3)=C1N)c2N Chemical compound Nc(c(C1=O)c(c(N)c2N)OC(c3ccccc3)=C1N)c2N OAZFKEIJWMNWND-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- This invention relates generally to a method for the prevention and treatment of diseases and conditions mediated by cyclooxygenase (COX) and lipoxygenase (LOX).
- COX cyclooxygenase
- LOX lipoxygenase
- the present invention relates to a novel composition of matter comprised of a mixture of a blend of two specific classes of compounds—Free-B-Ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions of the skin mediated by the COX and LOX pathways.
- Included in the present invention is a method for the prevention and treatment of COX and LOX mediated diseases and conditions, including but not limited to sun burns, thermal burns, acne, topical wounds, minor inflammatory conditions caused by fungal, microbial and viral infections, vitilago, systemic lupus erythromatosus, psoriasis, carcinoma, melanoma, as well as other mammal skin cancers, skin damage resulting from exposure to ultraviolet (UV) radiation, chemicals, heat, wind and dry environments, wrinkles, saggy skin, lines and dark circles around the eyes, dermatitis and other allergy related conditions of the skin.
- UV radiation ultraviolet
- Use of the composition described herein also affords the benefit of smooth and youthful skin with improved elasticity, reduced and delayed aging, enhanced youthful appearance and texture, and increased flexibility, firmness, smoothness and suppleness.
- UV radiation which has a wavelength from 200 nm to 400 nm.
- UVA which has a wavelength range from 320-400 nm
- UVB which has a wavelength range from 290-320 nm
- UVC which has a wavelength range from 100-290 nm, can cause damage but not tanning.
- AA arachidonic acid
- LOX lipoxygenase
- COX cyclooxygenase
- the enzymes responsible for generating these mediators of inflammation have become the targets in the current invention to develop topically administered therapeutic agents aimed at the dual inhibition of inflammation resulting from both pathways which contribute to the physiological and pathological processes of diseases and conditions such as sun burn, thermal burns, scald, acne, topical wounds, lupus erythromatosus, psoriasis, carcinoma, melanoma, and other mammalian skin cancers.
- COX-1 is a constitutive form of the enzyme that has been linked to the production of physiologically important prostaglandins, which help regulate normal physiological functions, such as platelet aggregation, protection of cell function in the stomach and maintenance of normal kidney function.
- COX inhibitors In addition to their use as anti-inflammatory agents, another potential role for COX inhibitors is in the treatment of cancer. Over expression of COX has been demonstrated in various human malignancies and inhibitors of COX have been shown to be efficacious in the treatment of animals with skin tumors. While the mechanism of action is not completely understood, the over expression of COX has been shown to inhibit apoptosis and increase the invasiveness of tumorgenic cell types. (Dempke et al. (2001) J. Can. Res. Clin. Oncol. 127:411-17; Moore and Simmons (2000) Current Med. Chem. 7:1131-1144). Up regulated COX production has been implicated in the generation of actinic keratosis and squamous cell carcinoma in skin.
- Topical application of anti-inflammatory drugs such as retinoids (Millikan (2003) J. Am. Acad. Dermatol. 4(2):75) and the COX inhibitor salicylic acid (Lee (2003) Dermnatol Surg 29(12):1196) have been clinically demonstrated as an effective and safe therapy for the treatment of acne.
- NSAIDs nonsteroidal anti-inflammatory drugs
- topical application of anti-inflammatory drugs have been clinically demonstrated as an effective and safe therapy for the treatment of acne.
- NSAIDs nonsteroidal anti-inflammatory drugs
- NSAIDs nonsteroidal anti-inflammatory drugs
- flavonoids include flavanols, flavones, flavan-3-ols (catechins), anthocyanins and isoflavones.
- Free-B-Ring flavones and flavonols are a specific class of flavonoids, which have no substituent groups on the aromatic B ring (referred to herein as Free-B-Ring flavonoids), as illustrated by the following general structure:
- R is an alkyl group having between 1-10 carbon atoms
- X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, fluoride, sulfate, phosphate, acetate, carbonate, etc.
- Free-B-Ring flavonoids are relatively rare. Out of 9,396 flavonoids synthesized or isolated from natural sources, only 231 Free-B-Ring flavonoids are known ( The Combined Chemical Dictionary , Chapman & Hall/CRC, Version 5:1 June 2001). Free-B-Ring flavonoids have been reported to have diverse biological activity. For example, galangin (3,5,7-trihydroxyflavone) acts as antioxidant and free radical scavenger and is believed to be a promising candidate for anti-genotoxicity and cancer chemoprevention. (Heo et al. (2001) Mutat. Res. 488(2):135-150).
- the Chinese medicinal plant, Scutellaria baicalensis contains significant amounts of Free-B-Ring flavonoids, including baicalein, baicalin, wogonin and baicalenoside.
- this plant has been used to treat a number of conditions including clearing away heat, purging fire, dampness-warm and summer fever syndromes; polydipsia resulting from high fever; carbuncle, sores and other pyogenic skin infections; upper respiratory infections, such as acute tonsillitis, laryngopharyngitis and scarlet fever; viral hepatitis; nephritis; pelvitis; dysentery; hematemesis and epistaxis.
- This plant has also traditionally been used to prevent miscarriage.
- Scutellaria baicalensis root extract has been formulated as a supplemental sun screen agent with additive effects of the cumulative SPFs of each individual component in a topical formulation (WO98/19651).
- Chrysin has been used for its anxiety reducing properties (U.S. Pat. No. 5,756,538).
- Anti-inflammatory flavonoids are used for the control and treatment of anorectal and colonic diseases (U.S. Pat. No. 5,858,371), and inhibition of lipoxygenase (U.S. Pat. No. 6,217,875). These compounds are also formulated with glucosamine collagen and other ingredients for repair and maintenance of connective tissue (U.S. Pat. No. 6,333,304).
- Flavonoid esters constitute active ingredients for cosmetic compositions (U.S. Pat. No. 6,235,294).
- U.S. application Ser. No. 10/091,362 filed Mar. 1, 2002, entitled “Identification of Free-B-Ring Flavonoids as Potent COX-2 Inhibitors,” and U.S. application Ser. No. 10/427,746, filed Jul.
- Japanese Pat. No. 63027435 describes the extraction, and enrichment of baicalein and Japanese Pat. No. 61050921 describes the purification of baicalin.
- Flavans include compounds illustrated by the following general structure:
- R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of —H, —OH, —SH, —OCH 3 , —SCH 3 , —OR, —SR, —NH 2 , —NRH, —NR 2 , —NR 3 + X ⁇ , esters of the mentioned substitution groups, including, but not limited to, gallate, acetate, cinnamoyl and hydroxyl-cinnamoyl esters, trihydroxybenzoyl esters and caffeoyl esters, and their chemical derivatives thereof; a carbon, oxygen, nitrogen or sulfur glycoside of a single or a combination of multiple sugars including, but not limited to, aldopentoses, methyl aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof; dimer, trimer and other polymerized flavans;
- R is an alkyl group having between 1-10 carbon atoms
- X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, and carbonate, etc.
- Catechin works both alone and in conjunction with other flavonoids found in tea, and has both antiviral and antioxidant activity. Catechin has been shown to be effective in the treatment of viral hepatitis. It also appears to prevent oxidative damage to the heart, kidney, lungs and spleen and has been shown to inhibit the growth of stomach cancer cells.
- Catechin and its isomer epicatechin inhibit prostaglandin endoperoxide synthase with an IC 50 value of 40 ⁇ M.
- IC 50 value 40 ⁇ M.
- Five flavan-3-ol derivatives, including (+)-catechin and gallocatechin, isolated from four plant species: Atuna racemosa, Syzygium carynocarpum, Syzygium malaccense and Vantanea peruviana exhibit equal to weaker inhibitory activity against COX-2, relative to COX-1, with IC 50 values ranging from 3.3 ⁇ M to 138 ⁇ M (Noreen et al. (1998) Planta Med. 64:520-524).
- (+)-Catechin isolated from the bark of Ceiba pentandra , inhibits COX-1 with an IC 50 value of 80 ⁇ M (Noreen et al. (1998) J. Nat. Prod. 61:8-12).
- Commercially available pure (+)-catechin inhibits COX-1 with an IC 50 value of around 183 to 279 ⁇ M depending upon the experimental conditions, with no selectivity for COX-2. (Noreen et al. (1998) J. Nat. Prod. 61:1-7).
- Green tea catechin when supplemented into the diets of Sprague dawley male rats, lowered the activity level of platelet PLA 2 and significantly reduced platelet cyclooxygenase levels.
- (+)-catechin from red wine results from the antioxidant properties of catechin, rather than inhibitory effects on intracellular enzymes, such as cyclooxygenase, lipoxygenase, or nitric oxide synthase (Bastianetto et al. (2000) Br. J. Pharmacol. 131:711-720).
- Catechin derivatives purified from green and black tea such as epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), epicatechin-3-gallate (ECG), and theaflavins showed inhibition of cyclooxygenase and lipoxygenase dependent metabolism of AA in human colon mucosa and colon tumor tissues (Hong et al.
- Acacia is a genus of leguminous trees and shrubs.
- the genus Acacia includes more than 1000 species belonging to the family of Leguminosae and the subfamily of Mimosoideae.
- Acacias are distributed worldwide in tropical and subtropical areas of Central and South America, Africa, parts of Asia, as well as, Australia, which has the largest number of endemic species.
- Acacias are very important economically, providing a source of tannins, gums, timber, fuel and fodder. Tannins, which are isolated primarily from bark, are used extensively for tanning hides and skins. Some Acacia barks are also used for flavoring local spirits. Some indigenous species like A.
- saponins are any of various plant glucosides that form soapy lathers when mixed and agitated with water. Saponins are used in detergents, foaming agents and emulsifiers. The flowers of some Acacia species are fragrant and used to make perfume. The heartwood of many Acacias is used for making agricultural implements and also provides a source of firewood. Acacia gums find extensive use in medicine and confectionary and as sizing and finishing materials in the textile industry.
- Flavonoids are the major class of compounds isolated from Acacias . Approximately 180 different flavonoids have been identified, 111 of which are flavans. Terpenoids are second largest class of compounds isolated from species of the Acacia genus, with 48 compounds having been identified. Other classes of compounds isolated from Acacia include, alkaloids (28), amino acids/peptides (20), tannins (16), carbohydrates (15), oxygen heterocycles (15) and aliphatic compounds (10). (Buckingham, The Combined Chemical Dictionary , Chapman & Hall CRC, version 5:2, December 2001).
- Phenolic compounds, particularly flavans are found in moderate to high concentrations in all Acacia species. (Abdulrazak et al. (2000) Journal of Animal Sciences. 13:935-940). Historically, most of the plants and extracts of the Acacia genus have been utilized as astringents to treat gastrointestinal disorders, diarrhea, indigestion and to stop bleeding. (Vautrin (1996) Universite Bourgogne (France) European abstract 58-01C:177; Saleem et al. (1998) Hamdard Midicus. 41:63-67). The bark and pods of Acacia arabica Willd. contain large quantities of tannins and have been utilized as astringents and expectorants.
- the extract from the bark of Acacia has been patented in Japan for external use as a whitening agent (Abe, JP10025238), as a glucosyl transferase inhibitor for dental applications (Abe, JP07242555), as a protein synthesis inhibitor (Fukai, JP 07165598), as an active oxygen scavenging agent for external skin preparations (Honda, JP 07017847, Bindra U.S. Pat. No. 6,1266,950), and as a hyaluronidase inhibitor for oral consumption to prevent inflammation, pollinosis and cough (Ogura, JP 07010768).
- the present invention includes methods that are effective in simultaneously inhibiting both the cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, for use in the prevention and treatment of diseases and conditions related to the skin.
- the method for the simultaneous dual inhibition of the COX and LOX enzymes is comprised administering, preferably topically, a composition comprised of a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof.
- This composition of matter is referred to herein as SoliprinTM.
- SoliprinTM This composition of matter is referred to herein as SoliprinTM.
- the efficacy of this method was demonstrated with purified enzymes, in different cell lines, in multiple animal models and eventually in a human clinical study.
- the ratio of the Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 of Free-B-Ring flavonoids:flavans to 0.1:99.9 Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90.
- the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is 80:20.
- the Free-B-Ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and the flavans are isolated from a plant or plants in the Acacia genus of plants.
- the present invention also includes methods for the prevention and treatment of COX and LOX mediated diseases and conditions of the skin.
- the method for preventing and treating COX and LOX mediated diseases and conditions of the skin is comprised of administering, preferably topically, to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants and a pharmaceutically acceptable carrier.
- the ratio of the Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 of Free-B-Ring flavonoids:flavans to 0.1:99.9 Free-B-Ring flavonoids:flavans.
- Free-B-Ring flavonoids also referred to herein as Free-B-Ring flavones and flavonols, that can be used in accordance with the following invention include compounds illustrated by the following general structure:
- R 1 , R 2 , R 3 , R 4, and R 5 are independently selected from the group consisting of —H, —OH, —SH, OR, —SR, —NH 2 , —NHR, —NR 2 , —NR 3 + X ⁇ , a carbon, oxygen, nitrogen or sulfur, glycoside of a single or a combination of multiple sugars including, but not limited to aldopentoses, methyl-aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof;
- R is selected from an alkyl group having between 1-10 carbon atoms
- X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, carbonate, etc.
- the Free-B-Ring flavonoids of this invention may be obtained by synthetic methods or extracted from the family of plants including, but not limited to Annonaceae, Asteraceae, Bignoniaceae, Combretaceae, Compositae, Euphorbiaceae, Labiatae, Lauranceae, Leguminosae, Moraceae, Pinaceae, Pteridaceae, Sinopteridaceae, Ulmaceae and Zingiberacea .
- the Free-B-Ring flavonoids can be extracted, concentrated, and purified from the following genus of high plants, including but not limited to Desmos, Achyrocline, Oroxylum, Buchenavia, Anaphalis, Cotula, Gnaphalium, Helichrysum, Centaurea, Eupatorium, Baccharis, Sapium, Scutellaria, Molsa, Colebrookea, Stachys, Origanum, Ziziphora, Lindera, Actinodaphne, Acacia, Derris, Glycyrrhiza, Millettia, Pongamia, Tephrosia, Artocarpus, Ficus, Pityrogramma, Notholaena, Pinus, Ulmus and Alpinia.
- R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of H, —OH, —SH, —OCH 3 , —SCH 3 , —OR, —SR, —NH 2 , —NRH, —NR 2 , —NR 3 + X ⁇ , esters of the mentioned substitution groups, including, but not limited to, gallate, acetate, cinnamoyl and hydroxyl-cinnamoyl esters, trihydroxybenzoyl esters and caffeoyl esters; thereof carbon, oxygen, nitrogen or sulfur glycoside of a single or a combination of multiple sugars including, but not limited to, aldopentoses, methyl aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof; dimer, trimer and other polymerized flavans;
- R is selected from an alkyl group having between 1-10 carbon atoms
- X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, carbonate, etc.
- the flavans of this invention may be obtained from a plant or plants selected from the genus of Acacia .
- the plant is selected from the group consisting of Acacia catechu, Acacia concinna, Acacia farnesiana, Acacia Senegal, Acacia speciosa, Acacia arabica, A. caesia, A. pennata, A. sinuata. A. mearnsii, A. picnantha, A. dealbata, A. auriculiformis, A. holoserecia and A. mangium.
- the present invention includes a method for preventing and treating a number of COX and LOX mediated diseases and conditions of the skin including, but not limited to sun burns, thermal burns, acne, topical wounds, minor inflammatory conditions caused by fungal, microbial and viral infections, vitilago, systemic lupus erythromatosus, psoriasis, carcinoma, melanoma, as well as other mammal skin cancers.
- the present invention includes a method for preventing and treating skin damage resulting from exposure to ultraviolet (UV) radiation, chemicals, heat, wind and dry environments.
- the present invention includes a method for preventing and treating wrinkles, saggy skin, lines and dark circles around the eyes, dermatitis and other allergy related conditions of the skin.
- the present invention further includes therapeutic compositions comprising the therapeutic agents of the present invention.
- the therapeutic compositions described herein can also be used to sooth sensitive skin and to provide smooth and youthful skin with improved elasticity, reduced and delayed aging, enhanced youthful appearance and texture, and increased flexibility, firmness, smoothness and suppleness.
- the method of prevention and treatment according to this invention comprises administering topically to a host in need thereof a therapeutically effective amount of the formulated Free-B-Ring flavonoids and flavans isolated from a single source or multiple sources.
- the purity of the individual and/or a mixture of multiple Free-B-Ring flavonoids and flavans includes, but is not limited to 0.01% to 100%, depending on the methodology used to obtain the compound(s).
- the present invention includes an evaluation of different compositions of Free-B-Ring flavonoids and flavans using enzymatic and in vivo models to optimize the formulation and obtain the desired physiological activity. The efficacy and safety of this formulation is also demonstrated in human clinical studies.
- the compositions of this invention can be administered by any method known to one of ordinary skill in the art.
- the modes of administration include, but are not limited to, enteral (oral) administration, parenteral (intravenous, subcutaneous, and intramuscular) administration and topical application.
- the method of treatment according to this invention comprises administering topically to a host in need thereof a therapeutically effective amount of a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants.
- FIG. 1 depicts graphically a profile of the inhibition of COX-1 and COX-2 by a standardized Free-B-Ring flavonoid extract (83% baicalin based on HPLC) which was isolated from Scutellaria baicalensis .
- the extract was examined for its inhibition of the peroxidase activity of recombinant ovine COX-1 ( ⁇ ) and ovine COX-2 ( ⁇ ).
- the data is presented as percent inhibition vs. inhibitor concentration ( ⁇ g/mL).
- the IC 50 for COX-1 was calculated as 0.24 ⁇ g/mL/unit of enzyme while the IC 50 for COX-2 was calculated as 0.48 ⁇ g/mL/unit.
- FIG. 2 depicts graphically a profile of the inhibition of COX-1 and COX-2 by the purified component baicalin which was isolated from Scutellaria baicalensis .
- the compound was examined for its inhibition of the peroxidase activity of recombinant ovine COX-1 ( ⁇ ) and ovine COX-2 ( ⁇ ). The data is presented as percent inhibition vs. inhibitor concentration ( ⁇ g/mL).
- the IC 50 for COX-1 was determined to be 0.44 ⁇ g/mL/unit of enzyme and the IC 50 for COX-2 was determined to be 0.28 ⁇ g/mL/unit.
- FIG. 3 depicts graphically a profile of the inhibition of COX-1 and COX-2 by the purified component baicalein isolated from Scutellaria baicalensis .
- the compound was examined for its inhibition of the peroxidase activity of recombinant ovine COX-1 ( ⁇ ) and ovine COX-2 ( ⁇ ). The data is presented as percent inhibition vs. inhibitor concentration ( ⁇ g/mL).
- the IC 50 for COX-1 was determined to be 0.18 ⁇ g/mL/unit of enzyme and the IC 50 for COX-2 was determined to be 0.28 ⁇ g/mL/unit.
- FIG. 4 depicts graphically a profile of the inhibition of COX-1 and COX-2 by a standardized flavan extract containing 50% total flavans which was isolated from Acacia catechu .
- the extract was examined for its inhibition of the peroxidase activity of recombinant ovine COX-1 ( ⁇ ) and ovine COX-2 ( ⁇ ).
- the data is presented as percent inhibition vs. inhibitor concentration ( ⁇ g/mL).
- the IC 50 for COX-1 was calculated as 0.17 ⁇ g/mL/unit of enzyme and the IC 50 for COX-2 was calculated as 0.41 ⁇ g/mL/unit.
- FIG. 5 depicts graphically a profile of the inhibition of COX-1 and COX-2 by the a composition of matter comprised of greater than 90% flavans isolated from Acacia catechu .
- the composition was examined for its inhibition of the peroxidase activity of recombinant ovine COX-1 ( ⁇ ) and ovine COX-2 ( ⁇ ). The data is presented as percent inhibition vs. inhibitor concentration ( ⁇ g/mL).
- the IC 50 for COX-1 was calculated as 0.11 ⁇ g/mL/unit of enzyme and the IC 50 for COX-2 was calculated as 0.42 ⁇ g/mL/unit.
- FIG. 6 depicts graphically a profile of the inhibition of COX-1 and COX-2 by a formulation produced by combining an extract of Free-B-Ring flavonoids isolated from the roots of Scutellaria baicalensis and an extract of flavans isolated from the bark of Acacia catechu in a ratio of 80:20.
- This composition of matter referred to hereinafter as SoliprinTM, was examined for its inhibition of the peroxidase activity of recombinant ovine COX-1 ( ⁇ ) and ovine COX-2 ( ⁇ ). The data is presented as percent inhibition vs. inhibitor concentration ( ⁇ g/mL).
- the IC 50 for COX-1 was calculated as 0.76 ⁇ g/mL/unit of enzyme and the IC 50 for COX-2 was calculated as 0.80 ⁇ g/mL/unit.
- FIG. 7 depicts graphically a profile of the inhibition of COX-1 and COX-2 by a formulation produced by combining an extract of Free-B-Ring flavonoids isolated from the roots of Scutellaria baicalensis and an extract of flavans isolated from the bark of Acacia catechu in a ratio of about 50:50.
- the composition, SoliprinTM was examined for its inhibition of the peroxidase activity of recombinant ovine COX-1 ( ⁇ ) and ovine COX-2 ( ⁇ ). The data is presented as percent inhibition vs. inhibitor concentration ( ⁇ g/mL).
- the IC 50 for COX-1 was calculated as 0.38 ⁇ g/mL/unit of enzyme and the IC 50 for COX-2 was determined to be 0.84 ⁇ g/mL/unit.
- FIG. 8 depicts graphically a profile of the inhibition of COX-1 and COX-2 by a formulation produced by combining an extract of Free-B-Ring flavonoids isolated from the roots of Scutellaria baicalensis and an extract of flavans isolated from the bark of Acacia catechu in a ratio of about 20:80.
- the composition, SoliprinTM was examined for its inhibition of the peroxidase activity of recombinant ovine COX-1 ( ⁇ ) and ovine COX-2 ( ⁇ ). The data is presented as percent inhibition vs. inhibitor concentration ( ⁇ g/mL).
- the IC 50 of this composition for COX-1 was 0.18 ⁇ g/mL/unit of enzyme and the IC 50 for COX-2 was 0.41 ⁇ g/mL/unit.
- FIG. 9 depicts graphically a profile of the inhibition of 5-LO by the flavan extract from Acacia catechu .
- the composition was examined for its inhibition of recombinant potato 5-lipoxygenase activity ( ⁇ ) as described in Example 4.
- the data is presented as percent inhibition of assays without inhibitor.
- the IC 50 for 5-LO was 1.38 ⁇ g/mL/unit of enzyme.
- FIG. 10 illustrates the High Pressure Liquid Chromatography (HPLC) chromatogram of a typical formulation comprised of a mixture of Free-B-Ring flavonoids isolated from the roots of Scutellaria baicalensis and flavans isolated from the bark of Acacia catechu in a ratio of 80:20 carried out under the conditions as described in Example 9.
- HPLC High Pressure Liquid Chromatography
- FIG. 11 depicts graphically the effect of increasing concentrations of SoliprinTM on the amount of LPS-induced newly synthesized LTB 4 ( ⁇ ) as determined by ELISA in THP-1 or HT-29 cells (ATCC) as described in Example 10.
- the SoliprinTM was produced through the combination of standardized extracts of Free-B-Ring flavonoids isolated from the roots of Scutellaria baicalensis and flavans isolated from the bark of Acacia catechu in a ratio of 80:20.
- the activity of the SoliprinTM formulation is expressed as % inhibition of induced LTB 4 synthesis.
- FIG. 12 compares the LTB 4 levels as determined by ELISA that remain in HT-29 cells after treatment with 3 ⁇ g/mL SoliprinTM in non-induced cells to treatment with 3 ⁇ g/mL ibuprofen as described in Example 10.
- the SoliprinTM formulation demonstrated 80% inhibition of LTB4 production in the HT-29 cells after two days of treatment.
- FIG. 13 illustrates graphically ear-swelling data as a measure of inhibition of inflammation as described in Example 11.
- SoliprinTM produced through the combination of standardized extracts of Free-B-Ring flavonoids isolated from the roots of Scutellaria baicalensis and flavans isolated from the bark of Acacia catechu in a ratio of 80:20 was compared to untreated mice and mice given indomethacin (1.5 ⁇ g/kg) via oral gavage. The data is presented as the difference in micron measurement of the untreated vs. the treated ear lobe for each mouse.
- FIG. 14 illustrates graphically the effect of 100 ⁇ g/kg of SoliprinTM, produced through the combination of standardized extracts of Free-B-Ring flavonoids isolated from the roots of Scutellaria baicalensis and flavans isolated from the bark of Acacia catechu in a ratio of 80:20 on the AA injected ankles of mice (SoliprinTM+arachidonic acid) compared to non-treated mice (no treatment+arachidonic acid), mice without AA injections (negative control) or mice that were injected with the liquid carrier (vehicle control).
- FIG. 15 depicts graphically the changes in hairless mice skin erythema scores in different treatment groups as a function of time following irradiation of the mice with UV light as described in Example 12.
- the mice in Groups B-1, A-1, B-2 and A-2 were treated with SoliprinTM either before (Groups B-1 and B-2) or after (A-1 and A-2) irradiation.
- the SoliprinTM was produced through the combination of standardized extracts of Free-B-Ring flavonoids isolated from the roots of Scutellaria baicalensis and flavans isolated from the bark of Acacia catechu in a ratio of 80:20.
- FIG. 15 it can be seen that topical applications of SoliprinTM, both before and after UV radiation, significantly reduced erythema scores as compared with the control group and the group that was administered the standard treatment agent-Sooth-a-caine.
- a or “an” entity refers to one or more of that entity; for example, a flavonoid refers to one or more flavonoids.
- a flavonoid refers to one or more flavonoids.
- the terms “a” or “an”, “one or more” and “at least one” are used interchangeably herein.
- Free-B-Ring Flavonoids as used herein are a specific class of flavonoids, which have no substitute groups on the aromatic B-ring, as illustrated by the following general structure:
- R 1 , R 2 , R 3 , R4, and R 5 are independently selected from the group consisting of —H, —OH, —SH, OR, —SR, —NH 2 , —NHR, —NR 2 , —NR 3 + X ⁇ , a carbon, oxygen, nitrogen or sulfur, glycoside of a single or a combination of multiple sugars including, but not limited to aldopentoses, methyl-aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof;
- R is an alkyl group having between 1-10 carbon atoms
- X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, carbonate, etc.
- Flavonoids as used herein refer to a specific class of flavonoids, which can be generally represented by the following general structure:
- R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of H, —OH,
- esters of substitution groups including, but not limited to, gallate, acetate, cinnamoyl and hydroxyl-cinnamoyl esters, trihydroxybenzoyl esters and caffeoyl esters and their chemical derivatives thereof; carbon, oxygen, nitrogen or sulfur glycoside of a single or a combination of multiple sugars including, but not limited to, aldopentoses, methyl aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof; dimer, trimer and other polymerized flavans;
- R is an alkyl group having between 1-10 carbon atoms
- X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, carbonate, etc.
- “Therapeutic” as used herein, includes treatment and/or prophylaxis. When used, therapeutic refers to humans as well as other animals.
- “Pharmaceutically or therapeutically effective dose or amount” refers to a dosage level sufficient to induce a desired biological result. That result may be the alleviation of the signs, symptoms or causes of a disease or any other alteration of a biological system that is desired.
- “Placebo” refers to the substitution of the pharmaceutically or therapeutically effective dose or amount dose sufficient to induce a desired biological that may alleviate the signs, symptoms or causes of a disease with a non-active substance.
- a “host” or “patient” is a living subject, human or animal, into which the compositions described herein are administered.
- the invention described herein may be used for veterinary as well as human applications and the terms “patient” or “host” should not be construed in a limiting manner.
- the dosage ranges can be determined as described below, taking into account the body weight of the animal.
- the current invention provides methods for the extraction (Example 1, Table 1) of plants that contain Free-B-Ring flavonoids and flavans with organic and aqueous solvents.
- the crude extracts were assayed for cyclooxygenase inhibitory activity (Example 2, Tables 2 and 3).
- Purified Free-B-Ring flavonoids and flavans demonstrated inhibitory activity against cyclooxygenase (COX) and lipoxygenase (LOX), respectively, as shown in Examples 3 and 4.
- Methods for analyzing and quantifying the extracts are described in Examples 5 and 6 and the procedures to generate standardized Free-B-Ring flavonoids and flavans from botanical origins are provided in Examples 7 and 8.
- the standardized Free-B-Ring flavonoid extract is comprised of the active compounds having a purity of between 1-99% (by weight) of total Free-B-Ring flavonoids as defined in Examples 1, 2, 5 and 8.
- Baicalin is the major active component in the extract, which accounts for approximately 50-90% (by weight) of the total Free-B-Ring flavonoids.
- the standardized extract contains >70% total Free-B-Ring flavonoids in which >75% of the Free-B-Ring flavonoids is baicalin.
- the standardized flavan extract is comprised of the active compounds having a purity of between 1-99% (by weight) total flavans as defined in Examples 1, 4, 6 and 7. Catechin is the major active component in the extract and accounts for 50-95% (by weight) of the total flavans.
- the standardized flavan extract contains >80% total flavans in which >70% of flavans is catechin.
- SoliprinTM is produced by mixing the above two extracts or synthetic compounds in a ratio from 99:1 to 1:99.
- the preferred ratios of Free-B-Ring flavonoids to flavans are 80:20 as defined in Example 9 and Table 10 and 15:85 as defined in Example 9.
- the concentration of Free-B-Ring flavonoids in SoliprinTM can be from about 1% to 99% and the concentration of flavans in SoliprinTM can be from 99% to 1%.
- the concentration of total Free-B-Ring flavonoids in SoliprinTM is approximately 20% with a baicalin content of approximately 15% of total weight of the SoliprinTM; and the concentration of total flavans in SoliprinTM is approximately 75% with a catechin content of approximately 70%.
- the total active components (Free-B-Ring flavonoids plus flavans) in SoliprinTM are >90% of the total weight.
- the present invention includes methods that are effective in simultaneously inhibiting both the cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, for use in the prevention and treatment of diseases and conditions related to the skin.
- the method for the simultaneous dual inhibition of the COX and LOX enzymes is comprised of administering, preferably topically a composition comprised of a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof.
- This composition of matter is referred to herein as SoliprinTM.
- the efficacy of this method was demonstrated with purified enzymes, in different cell lines, in multiple animal models and eventually in a human clinical study.
- the present invention also includes methods for the prevention and treatment of COX and LOX mediated diseases and conditions of the skin.
- the method for preventing and treating COX and LOX mediated diseases and conditions of the skin is comprised of administering, preferably topically, to a host in need thereof an effective amount of a composition comprised of a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants and a pharmaceutically acceptable carrier.
- the ratio of the Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 of Free-B-Ring flavonoids:flavans to 0.1:99.9 Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90.
- the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is 20:80.
- the Free-B-Ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and the flavans are isolated from a plant or plants in the Acacia genus of plants.
- the present invention includes a method for preventing and treating a number of COX and LOX mediated diseases and conditions of the skin including, but not limited to sun burns, thermal burns, acne, topical wounds, minor inflammatory conditions caused by fungal, microbial and viral infections, vitilago, systemic lupus erythromatosus, psoriasis, carcinoma, melanoma, as well as other mammal skin cancers.
- the present invention includes a method for preventing and treating skin damage resulting from exposure to UV radiation, chemicals, heat, wind and dry environments.
- the present invention includes a method for preventing and treating wrinkles, saggy skin, lines and dark circles around the eyes, dermatitis and other allergy related conditions of the skin.
- the present invention further includes therapeutic compositions comprising the therapeutic agents of the present invention.
- the therapeutic compositions described herein can be used to sooth sensitive skin and to provide smooth and youthful skin with improved elasticity, reduced and delayed aging, enhanced youthful appearance and texture, and increased flexibility, firmness, smoothness and suppleness.
- the Free-B-Ring flavonoids that can be used in accordance with the instant invention include compounds illustrated by the general structure set forth above.
- the Free-B-Ring flavonoids of this invention may be obtained by synthetic methods or may be isolated from the family of plants including, but not limited to Annonaceae, Asteraceae, Bignoniaceae, Combretaceae, Compositae, Euphorbiaceae, Labiatae, Lauranceae, Leguminosae, Moraceae, Pinaceae, Pteridaceae, Sinopteridaceae, Ulmaceae , and Zingiberacea .
- the Free-B-Ring flavonoids can be extracted, concentrated, and purified from the following genus of high plants, including but not limited to Desmos, Achyrocline, Oroxylum, Buchenavia, Anaphalis, Cotula, Gnaphalium, Helichrysum, Centaurea, Eupatorium, Baccharis, Sapium, Scutellaria, Molsa, Colebrookea, Stachys, Origanum, Ziziphora, Lindera, Actinodaphne, Acacia, Derris, Glycyrrhiza, Millettia, Pongamia, Tephrosia, Artocarpus, Ficus, Pityrogramma, Notholaena, Pinus, Ulmus and Alpinia.
- the flavans can be found in different parts of plants, including but not limited to stems, stem barks, trunks, trunk barks, twigs, tubers, roots, root barks, young shoots, seeds, rhizomes, flowers and other reproductive organs, leaves and other aerial parts. Methods for the isolation and purification of flavans are described in U.S. application Ser. No. 10/104,477, filed Mar. 22, 2002, entitled “Isolation of a Dual Cox-2 and 5-Lipoxygenase Inhibitor from Acacia ,” which is incorporated herein by reference in its entirety.
- the biochemical assay used to measure inhibition of COX, relies on the protein's peroxidase activity in the presence of heme and arachidonic acid.
- This study which is described in Example 3, showed that the purified Free-B-Ring flavonoids, baicalin and baicalein isolated from Scutellaria baicalensis and the flavan extract isolated from Acacia catechu , and each individual standardized extract containing high concentrations of Free-B-Ring flavonoids and flavans inhibited COX activity (FIGS. 1-5).
- compositions having different ratios of each of the individual standardized extracts i.e., 80:20, 50:50 and 20:80 Free-B-Ring flavonoids:flavans
- were all highly effective at inhibiting the COX activity in vitro (FIGS. 6-8).
- the inhibition of LOX activity by a flavan extract isolated from Acacia catechu was assessed using a lipoxygenase screening assay in vitro as described in Example 4. The results are illustrated in FIG. 9.
- cell assays that targeted inhibition of compounds in the breakdown of arachidonic acid in the LOX pathway, namely leukotriene B4 were performed using a SoliprinTM sample as described in Example 10.
- the LTB 4 inhibition results by SoliprinTM are illustrated in FIGS. 11 and 12.
- the erythema scores of the hairless mice from four SoliprinTM groups in both concentrations and regardless the applications time as before or after UV exposure, all showed much less redness in smaller skin areas as compared to severe and extended erythema in both the control group and the group that was treated with Sooth-A Cain.
- Example 13 (Tables 11 and 12) describes a general method for the preparation of a SoliprinTM cream using pharmacologically, dermatologically and cosmetic acceptable excipients. For purposes of illustration this Example provides a detailed procedure for the preparation of both a 0.5 wt % and 1.5 wt % SoliprinTM cream. Finally, both of the SoliprinTM creams prepared as described in Example 13 were evaluated on human skin for potential irritation and induction of contact sensitization. A total of 97 and 101 subjects completed induction and challenge with the 0.5% and 1.5% SoliprinTM creams, respectively. Test results show that SoliprinTM creams at 0.5% and 1.5% concentration produced minimal irritation and did not elicit evidence of induced contact sensitization.
- the present invention includes methods that are effective in simultaneously inhibiting both the COX and LOX enzymes.
- the method for the simultaneous dual inhibition of the COX and LOX pathways is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof.
- the ratio of Free-B-Ring flavonoids to flavans in the composition can be in the range of 99:1 Free-B-Ring flavonoids:flavans to 1:99 of Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70,-20:80 and 10:90.
- the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 20:80.
- the Free-B-Ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and flavans are isolated from a plant or plants in the Acacia genus of plants.
- the present further includes methods for the prevention and treatment of COX and LOX mediated skin diseases and conditions.
- the method for preventing and treating COX and LOX mediated skin diseases and conditions is comprised of administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants together with a pharmaceutically acceptable carrier.
- the ratio of Free-B-Ring flavonoids to flavans can be in the range of 99:1 Free-B-Ring flavonoids:flavans to 1:99 of Free-B-Ring flavonoids:flavans.
- the present invention further includes therapeutic compositions comprising the therapeutic agents of the present invention including various formulations thereof. Methods for the preparation of these compositions, together with methods for the determination of their purity and specific composition are described in Examples 5-9 and FIG. 10.
- doses of the mixture of Free-B-Ring flavonoids and/or flavans containing that same are an efficacious, nontoxic quantity generally selected from the range of 0.001% to 100% based on total weight of the topical formulation. Persons skilled in the art using routine clinical testing are able to determine optimum doses for the particular ailment being treated.
- the composition can also include an adjuvant or a carrier.
- adjuvants are typically substances that generally enhance the biological response of a mammal to a specific bioactive agent. Suitable adjuvants include, but are not limited to, Freund's adjuvant; other bacterial cell wall components; aluminum-based salts; calcium-based salts; silica; polynucleotides; toxoids; serum proteins; viral coat proteins; other bacterial-derived preparations; gamma interferon; block copolymer adjuvants, such as Hunter's Titermax adjuvant (Vaxcel.TM., Inc.
- Carriers are typically compounds that increase the half-life of a therapeutic composition in the treated host. Suitable carriers include, but are not limited to, polymeric controlled release formulations, biodegradable implants, liposomes, bacteria, viruses, oils, esters, and glycols.
- the composition is prepared as a controlled release formulation, which slowly releases the composition of the present invention into the host.
- a controlled release formulation comprises a composition of the present invention in a controlled release vehicle.
- Suitable controlled release vehicles will be known to those skilled in the art.
- Preferred controlled release formulations are biodegradable (i.e., bioerodible).
- the therapeutic agents of the instant invention are preferably administered topically by any suitable means, known to those of skill in the art for topically administering therapeutic compositions including, but not limited to as an ointment, gel, lotion, or cream base or as an emulsion, as a patch, dressing or mask, a nonsticking gauze, a bandage, a swab or a cloth wipe.
- Such topical application can be locally administered to any affected area, using any standard means known for topical administration.
- a therapeutic composition can be administered in a variety of unit dosage forms depending upon the method of administration.
- a therapeutic composition of the present invention can be formulated in an excipient of the present invention.
- a therapeutic reagent of the present invention can be administered to any host, preferably to mammals, and more preferably to humans. The particular mode of administration will depend on the condition to be treated.
- a suitable ointment is comprised of the desired concentration of the mixture of Free-B-Ring flavonoids and flavans, that is an efficacious, nontoxic quantity generally selected from the range of 0.001% to 100% based on total weight of the topical formulation, from 65 to 100% (preferably 75 to 96%) of white soft paraffin, from 0 to 15% of liquid paraffin, and from 0 to 7% (preferably 3 to 7%) of lanolin or a derivative of synthetic equivalent thereof.
- the ointment may comprise a polyethylene—liquid paraffin matrix.
- a suitable cream is comprised of an emulsifying system together with the desired concentration of the mixture of Free-B-Ring flavonoids and flavans as provided above.
- the emulsifying system is preferably comprised of from 2 to 10% of polyoxyethylene alcohols (e.g.
- Example 13 describes the formulation of two different concentrations of the composition of this invention as a cream and Example 14 describes a study undertaken to evaluate the cream for irritation and sensitization of the skin. From this study it was determined that SoliprinTM is a safe composition that can be applied topically at an efficacious concentration without causing irritation or sensitization of the skin.
- a suitable gel is comprised of a semi-solid system in which a liquid phase is constrained within a three dimensional polymeric matrix with a high degree of cross-linking.
- the liquid phase may be comprised of water, together with the desired amount of the mixture of Free-B-Ring flavonoids and flavans, from 0 to 20% of water-miscible additives, for example glycerol, polyethylene glycol, or propylene glycol, and from 0.1 to 10%, preferably from 0.5 to 2%, of a thickening agent, which may be a natural product, for example tragacanth, pectin, carrageen, agar and alginic acid, or a synthetic or semi-synthetic compound, for example methylcellulose and carboxypolymethylene (carbopol); together with one or more preservatives, for example from 0.1 to 2% of methyl 4-hydroxybenzoate (methyl paraben) or phenoxyethanol-differential.
- Another suitable base is comprised of the desired amount of the mixture of Free-B-Ring flavonoids and flavans, together with from 70 to 90% of polyethylene glycol (for example, polyethylene glycol ointment containing 40% of polyethylene glycol 3350 and 60% of polyethylene glycol 400, prepared in accordance with the U.S. National Formulary (USNF)), from 5 to 20% of water, from 0.02 to 0.25% of an anti-oxidant (for example butylated hydroxytoluene), and from 0.005 to 0.1% of a chelating agent (for example ethylenediamine tetraacetic acid (EDTA)).
- polyethylene glycol for example, polyethylene glycol ointment containing 40% of polyethylene glycol 3350 and 60% of polyethylene glycol 400, prepared in accordance with the U.S. National Formulary (USNF)
- an anti-oxidant for example butylated hydroxytoluene
- a chelating agent for example ethylenediamine tetraacetic
- soft paraffin as used above encompasses the cream or ointment bases white soft paraffin and yellow soft paraffin.
- lanolin encompasses native wool fat and purified wool fat. Derivatives of lanolin include in particular lanolins which have been chemically modified in order to alter their physical or chemical properties and synthetic equivalents of lanolin include in particular synthetic or semisynthetic compounds and mixtures which are known and used in the pharmaceutical and cosmetic arts as alternatives to lanolin and may, for example, be referred to as lanolin substitutes.
- compositions of the invention may be produced by conventional pharmaceutical techniques.
- the aforementioned compositions may conveniently be prepared by mixing together at an elevated temperature, preferably 60-70° C., the soft paraffin, liquid paraffin if present, and lanolin or derivative or synthetic equivalent thereof.
- the mixture may then be cooled to room temperature, and, after addition of the hydrated crystalline calcium salt of mupirocin, together with the corticosteroid and any other ingredients, stirred to ensure adequate dispersion.
- the specific dose is calculated according to the approximate body weight of the host. Further refinement of the calculations necessary to determine the appropriate dosage for treatment involving each of the above mentioned formulations is routinely made by those of ordinary skill in the art and is within the scope of tasks routinely performed by them without undue experimentation, especially in light of the dosage information and assays disclosed herein. These dosages may be ascertained through use of the established assays for determining dosages utilized in conjunction with appropriate dose-response data.
- compositions of this invention can be administered by any method known to one of ordinary skill in the art.
- the modes of administration include, but are not limited to, enteral (oral) administration, parenteral (intravenous, subcutaneous, and intramuscular) administration and topical application.
- the method of treatment according to this invention comprises administering internally or topically to a patient in need thereof a therapeutically effective amount of a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants.
- the composition is administered topically.
- bioassay directed screening process for the identification of specific COX-2 inhibitors was designed to assay the peroxidase activity of the enzyme as described below.
- Peroxidase Assay The assay to detect inhibitors of COX-2 was modified for a high throughput platform (Raz). Briefly, recombinant ovine COX-2 (Cayman) in peroxidase buffer (100 mM TBS, 5 mM EDTA, 1 ⁇ M Heme, 1 mg epinephrine, 0.094% phenol) was incubated with extract (1:500 dilution) for 15 minutes. Quantablu (Pierce) substrate was added and allowed to develop for 45 minutes at 25° C. Luminescence was then read using a Wallac Victor 2 plate reader. The results are presented in Table 2.
- Table 2 sets forth the inhibition of enzyme by the organic and aqueous extracts obtained from five plant species, including the bark of Acacia catechu , roots of two Scutellaria species and extracts from three other plant species, which are comprised of structurally similar Free-B-Ring flavonoids. Data is presented as the percent of peroxidase activity relative to the recombinant ovine COX-2 enzyme and substrate alone. The percent inhibition by the organic extract ranged from 30% to 90%.
- IC 50 is defined as the concentration at which 50% inhibition of enzyme activity in relation to the control is achieved by a particular inhibitor. In these experiments, IC 50 values were found to range from 6 to 50 ⁇ g/mL and 7 to 80 ⁇ g/mL for the COX-2 and COX-1 enzymes, respectively, as set forth in Table 3. Comparison of the IC 50 values of COX-2 and COX-1 demonstrates the specificity of the organic extracts from various plants for each of these enzymes.
- the organic extract of Scutellaria lateriflora shows preferential inhibition of COX-2 over COX-1 with IC 50 values of 30 and 80 ⁇ g/mL, respectively. While some extracts demonstrate preferential inhibition of COX-2, others do not. Examination of the HTP fractions and purified compounds from these fractions is necessary to determine the true specificity of inhibition for these extracts and compounds.
- Each inhibitor taken from a 10 mg/mL stock solution in 100% DMSO, was tested in triplicate at room temperature using the following range of concentrations: 0, 0.1, 1, 5, 10, 20, 50, 100, and 500 ⁇ g/mL.
- 150 ⁇ L of 100 mM Tris-HCl, pH 7.5 was added along with 10 ⁇ L of 22 ⁇ M Hematin diluted in tris buffer, 10 ⁇ L of inhibitor diluted in DMSO and 25 units of either the COX-1 or COX-2 enzyme.
- the components were mixed for 10 seconds on a rotating platform, followed by the addition of 20 ⁇ L of 2 mM N,N,N′N′-tetramethyl-p-phenylenediamine dihydrochloride (TMPD) and 20 ⁇ L of 1.1 mM arachidonic acid to initiate the reaction.
- TMPD N,N,N′N′-tetramethyl-p-phenylenediamine dihydrochloride
- TMPD N,N,N′N′-tetramethyl-p-phenylenediamine dihydrochloride
- arachidonic acid 20 ⁇ L of 1.1 mM arachidonic acid
- FIGS. 1, 2 and 3 The dose responses and IC 50 values for a standardized Free-B-Ring flavonoid extract, baicalin, and baicalein isolated from the roots of Scutellaria baicalensis are provided in FIGS. 1, 2 and 3 , respectively.
- the dose responses and IC 50 values for two standardized flavan extract (50% and >90% flavans, respectively) isolated from the heartwood of Acacia catechu are provided in FIGS. 4 and 5, respectively.
- FIGS. 4 and 5 The dose responses and IC 50 values for three formulations of Free-B-Ring flavonoids and flavans of varying composition are provided in FIG. 6 (80:20 blending), FIG. 7 (50:50 blending) and FIG. 8 (20:80 blending), respectively.
- catechu containing >90% flavans directly inhibited LOX in vitro The 15-LO from soybeans normally used in the kit was replaced with potato LOX, after a buffer change from phosphate to a tris -based buffer using microfiltration was performed.
- This assay detects the formation of hydroperoxides through an oxygen sensing chromagen. Briefly, the assay was performed in triplicate by adding 90 ⁇ L of 0.17 units/ ⁇ L potato 5-LO, 20 ⁇ L of 1.1 mM AA, 100 ⁇ L of oxygen-sensing chromagen and 10 ⁇ L of purified flavan inhibitor to final concentrations ranging from 0 to 500 ⁇ g/mL.
- the IC 50 for 5-LO inhibition from this composition was determined to be 1.38 ⁇ g/mL/unit of enzyme. The results are set forth in FIG. 9.
- mice were scored on level of erythema (redness) using the following scale: 0—no visible erythema; 1—very slight erythema; 2—well defined erythema; 3—severe erythema; and 4—tumor formation. Erythema was scored by eye for each group. The results are set forth in FIG. 15. With reference to FIG. 15 it can be seen that the control group (Group 1) had severe redness on day 3 (72 hours after the three day exposure to UV radiation). The Sooth-a-caine group also had maximum redness on day 3 (Group 2). The redness for the SoliprinTM treated groups (Groups 3-6) never exceeded a score of 2. These scores, though subjective, show that SoliprinTM is effective in both preventing and treating UV caused skin erythema.
- Photographs of representative mice on day four clearly demonstrate differences between the control group, the Sooth-a-cainTM treated groups and the SoliprinTM treated groups (data not shown).
- the control group and Sooth-a-cainTM treated animals exhibited very extensive patterns and redness of erythema compared to the animals treated with the SoliprinTM formulation both before and after UV exposure.
- the animals treated before UV irradiation with 5 mg/mL SoliprinTM exhibited the least amount of erythema as compared to all of the other animals.
- SoliprinTM (Lot #A1904) was dissolved in water at room temperature and homogenized with a blender until it was fully dispersed in solution (approximately 5 minutes). At room temperature and without stirring or agitating the solution, Ultrez-21 carbomer was added by sprinkling onto the surface of the solution and allowing it to fully wet (no white areas visible) and fall into the solution. With gentle stirring, the solution was then heated to 40° C. and glycerin was added (Part A). The mixture was then stirred for an additional 5 minutes. The remaining components (Part B) were weighed and heated to 40° C. while mixing.
- Part B the remaining components
- Part A the remaining components
- Part B the remaining components
- the emulsion was cooled to 30° C. and the pH was adjusted to approximately 5.5 (5.3 to 5.7) by titrating with neutralizer while stirring with a stir bar and/or spatula.
- the emulsion became highly viscous due to neutralization-induced conformational change of the carbomer.
- the emulsion eventually achieved a suitable viscosity for an emulsion cream.
- the emulsion cream was then mixed until uniform after which it was poured into a clean storage vessel and stored at 2° to 8° C. for one month.
- the SoliprinTM was tested on human skin using an adaptation of the Draize Patch Test (Marzulli and Maibach (1977) Contact Allergy: Predictive Testing in Humans. In Advances in Modem Toxicology, Dermatotoxicology and Pharmacology. Eds. Marzulli, F. N and Maibach, H. I. 4, 353-372).
- the test sites were located on the upper arm or the paraspinal region of the back.
- Each test article had an induction site and a challenge site.
- the induction site was comprised of two sub-sites: an original-site and a move-site.
- Patches which contains 0.2 ml of Soliprin cream on each patch, were applied repeatedly to the original-site unless a sufficiently strong irritation reaction developed, requiring the patch to be applied to the move-site. Patches were applied by a clinical research institute and were removed and discarded by the subjects approximately 24 or 48/72 hours later.
- repetitive application of the test article to the same site on the skin and a total of 9 induction patches were applied within a 4-week period. The rest period was 10 to 21 days between application of the last induction patch and application of the challenge patch. During this time no test article or any other material was applied to the test area.
- the test article was applied to a naive site on the opposite side of the body and discarded by the subjects approximately 24 or 48 hours later.
- SoliprinTM is a safe ingredient that can be applied topically to human skin at an efficacious concentration without causing irritation or sensitization.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/817,330 US20040220119A1 (en) | 2003-04-04 | 2004-04-02 | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
US13/028,853 US8790724B2 (en) | 2003-04-04 | 2011-02-16 | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
US14/445,688 US9622964B2 (en) | 2003-04-04 | 2014-07-29 | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46073603P | 2003-04-04 | 2003-04-04 | |
US10/817,330 US20040220119A1 (en) | 2003-04-04 | 2004-04-02 | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/028,853 Division US8790724B2 (en) | 2003-04-04 | 2011-02-16 | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040220119A1 true US20040220119A1 (en) | 2004-11-04 |
Family
ID=33159803
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/817,330 Abandoned US20040220119A1 (en) | 2003-04-04 | 2004-04-02 | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
US13/028,853 Expired - Lifetime US8790724B2 (en) | 2003-04-04 | 2011-02-16 | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
US14/445,688 Active 2024-07-29 US9622964B2 (en) | 2003-04-04 | 2014-07-29 | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/028,853 Expired - Lifetime US8790724B2 (en) | 2003-04-04 | 2011-02-16 | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
US14/445,688 Active 2024-07-29 US9622964B2 (en) | 2003-04-04 | 2014-07-29 | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
Country Status (9)
Country | Link |
---|---|
US (3) | US20040220119A1 (ko) |
EP (1) | EP1631304A4 (ko) |
JP (1) | JP4769184B2 (ko) |
KR (1) | KR101151322B1 (ko) |
CN (1) | CN1798568B (ko) |
AU (1) | AU2004228021B2 (ko) |
BR (1) | BRPI0409179A (ko) |
CA (1) | CA2521429A1 (ko) |
WO (1) | WO2004089392A1 (ko) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060079467A1 (en) * | 2002-04-30 | 2006-04-13 | Unigen Pharmaceuticals, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
US20060204596A1 (en) * | 2005-03-10 | 2006-09-14 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-Ring flavonoids and flavans as a therapeutic agent |
US20060222671A1 (en) * | 2005-03-30 | 2006-10-05 | Astion Development A/S | Dermatological compositions and salts for the treatment of dermatological diseases |
EP1849467A1 (en) * | 2005-02-01 | 2007-10-31 | Shanghai Gloriayx Biopharmaceuticals Co., Ltd | The synergistically pharmaceutical composition of baicalein and baicalin for inhibiting tumor |
US20090280200A1 (en) * | 2008-05-08 | 2009-11-12 | Industrial Technology Research Institute | Herbal extracts which induce immune cells to produce interferon and activate toll-like receptors |
US20100015257A1 (en) * | 2006-10-12 | 2010-01-21 | Unigen, Inc. | Composition For Treating Atopic Dermatitis Comprising Extracts Of Bamboo And Scutellaria |
US20110044920A1 (en) * | 2009-08-07 | 2011-02-24 | Mary Kay Inc. | Topical skin care formulations |
WO2011073961A1 (en) | 2009-12-15 | 2011-06-23 | Natura Cosmeticos S.A | Process for obtaining a standardised extract of quercetin and 3-0-methylquercetin from flowers of macela (achyrocline satureioides), and cosmetic and pharmaceutical compositions comprising said extract |
US8568799B2 (en) | 2002-03-22 | 2013-10-29 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from acacia |
US8790724B2 (en) | 2003-04-04 | 2014-07-29 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
US9370544B2 (en) | 2002-04-30 | 2016-06-21 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
CN114129495A (zh) * | 2021-12-10 | 2022-03-04 | 北京安德普泰医疗科技有限公司 | 一种抗炎舒敏修护组合物及其制备方法和应用 |
DE202022106782U1 (de) | 2022-12-03 | 2022-12-19 | Mohammed Azeemuddin | Antiurolithiatische, antiosteoporotische, antidiabetische und entzündungshemmende Zusammensetzung eines Polykräuterextraktes |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7972632B2 (en) | 2003-02-28 | 2011-07-05 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
US8034387B2 (en) | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
FR2869229B1 (fr) | 2004-04-26 | 2006-08-25 | Sederma Soc Par Actions Simpli | Utilisation d'un inducteur des ugt par voie topique |
FR2873026B1 (fr) * | 2004-07-13 | 2009-10-30 | Oreal | Procede de traitement cosmetique pour prevenir ou retarder les signes du vieillissement |
CN1988882A (zh) * | 2004-07-23 | 2007-06-27 | 宝洁公司 | 基于基底的护肤制品 |
US20060140881A1 (en) | 2004-12-22 | 2006-06-29 | Guofeng Xu | Oral care compositions containing flavonoids and flavans |
JP2006321730A (ja) * | 2005-05-17 | 2006-11-30 | Maruzen Pharmaceut Co Ltd | 抗酸化剤及び抗老化剤、並びに皮膚化粧料及び飲食物 |
AU2006321727A1 (en) * | 2005-12-09 | 2007-06-14 | Metaproteomics, Llc | Protein kinase modulation by hops and Acacia products |
US7855200B2 (en) | 2006-01-09 | 2010-12-21 | Council Of Scientific And Industrial Research | Method for treatment of gastric ulcers and ulcers induced by aspirin |
JP5004529B2 (ja) * | 2006-08-04 | 2012-08-22 | 株式会社日清製粉グループ本社 | ヒスタミン遊離抑制剤 |
FR2906716B1 (fr) * | 2006-10-06 | 2013-05-17 | Clarins Lab | Utilisation d'une composition cosmetique pour le soin des peaux grasses. |
JP5220346B2 (ja) * | 2007-05-28 | 2013-06-26 | 丸善製薬株式会社 | 皮膚化粧料 |
KR100902338B1 (ko) * | 2007-07-26 | 2009-06-12 | 한국과학기술연구원 | 민둥아까시 추출물, 이의 분획물, 또는 상기 분획물에서분리한 화합물들을 유효성분으로 함유하는 조성물 |
KR101069907B1 (ko) * | 2008-09-04 | 2011-10-05 | 재단법인 제주테크노파크 | 비목나무 유래 추출물, 분획물 또는 화합물을 함유하는 피부 미백용 조성물 |
CN101491533B (zh) * | 2008-12-18 | 2011-05-04 | 复旦大学附属中山医院 | 黄芩苷在制药中的应用 |
FR2953135B1 (fr) * | 2009-11-30 | 2012-05-11 | Expanscience Lab | Extrait de graines d'acacia macrostachya et compositions cosmetiques, pharmaceutiques, dermatologiques, nutraceutiques ou alimentaires le comprenant |
US20120201768A1 (en) * | 2010-09-10 | 2012-08-09 | Cheri Lynn Swanson | Cosmetic compositions comprising ficus serum fraction and methods to reduce the appearance of skin hyperpigmentation |
ES2645983T3 (es) * | 2010-09-10 | 2017-12-11 | Isp Investments Inc. | Composiciones bioactivas que comprenden una fracción de suero de ficus y métodos para reducir la aparición de hiperpigmentación de la piel |
JP2012176923A (ja) * | 2011-02-28 | 2012-09-13 | Kose Corp | 抗酸化剤、ハリ・タルミ改善剤、ラジカル消去剤、エラスターゼ活性阻害剤、並びに抗老化剤 |
CN104274831A (zh) * | 2013-07-10 | 2015-01-14 | 苏德培 | 一种基于天然衍生肽和炎症抑制剂和/或抗氧化化合物的组合物 |
KR102013163B1 (ko) * | 2013-08-14 | 2019-08-22 | 주식회사 엘지생활건강 | 피부 재생, 주름개선, 항산화 및 피부 미백용 조성물 |
AU2014330796B2 (en) * | 2013-10-03 | 2020-04-30 | University Of Pretoria | Extracts and compositions of Helichrysum odoratissimum for preventing and treating skin cancers |
KR102111752B1 (ko) * | 2013-11-15 | 2020-05-15 | 주식회사 엘지생활건강 | 콜라겐 합성 촉진용 조성물 |
KR101569772B1 (ko) | 2014-01-08 | 2015-11-17 | 주식회사 엘지생활건강 | 우고닌 또는 이의 약학적으로 허용 가능한 염을 포함하는 다크서클 개선용 화장료 조성물 |
US10492831B2 (en) | 2014-02-21 | 2019-12-03 | Warren R. Hultquist | Skin care methods, systems, and devices |
WO2016010440A1 (en) * | 2014-07-18 | 2016-01-21 | Manuka Health New Zealand Limited | Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health |
CN104721210B (zh) * | 2015-03-16 | 2017-10-13 | 中国药科大学 | 千层纸素苷在制备抗肿瘤转移药中的应用 |
US10493020B2 (en) | 2016-04-14 | 2019-12-03 | The Procter & Gamble Company | Method of improving the appearance of periorbital dyschromia |
CN106333943A (zh) * | 2016-11-11 | 2017-01-18 | 中国药科大学 | 一种千层纸素制剂 |
CN112704675A (zh) * | 2016-11-11 | 2021-04-27 | 中国药科大学 | 千层纸素在制备靶向作用肝癌细胞甲胎蛋白的抑制剂中的应用 |
EP4188408A1 (en) | 2020-07-30 | 2023-06-07 | Unigen, Inc. | A standardized bioflavonoid composition for regulation of homeostasis of host defense mechanism |
US20230293414A1 (en) * | 2020-08-07 | 2023-09-21 | Hope Permanente, Llc | Use of cyclin-dependent kinase (cdk) inhibitors for the slowdown or prevention of biological aging |
Citations (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3686872A (en) * | 1970-06-30 | 1972-08-29 | Anthony James Whitworth | Soil grouting process |
US3706581A (en) * | 1970-10-05 | 1972-12-19 | Borden Co | Soil grouting process and composition |
US4268517A (en) * | 1979-08-30 | 1981-05-19 | Continental Pharma | Pharmaceutical composition and therapeutical method for treating degenerative affections of the articular cartilage |
US4374824A (en) * | 1981-01-27 | 1983-02-22 | Krishan Dyal Mathur | Dentifrice |
US4946684A (en) * | 1989-06-20 | 1990-08-07 | American Home Products Corporation | Fast dissolving dosage forms |
US5443983A (en) * | 1986-08-08 | 1995-08-22 | Regents Of The University Of Minnesota | Method of culturing lymphocytes and method of treatment using such lymphocytes |
US5470589A (en) * | 1990-04-25 | 1995-11-28 | Traditional Chinese Medicine Research Laboratory, Inc. | Hardening agent for affected tissues of the digestive system |
US5545411A (en) * | 1994-12-16 | 1996-08-13 | Bristol-Myers Squibb Company | Method for lowering viscosity by use of gum acacia |
US5605929A (en) * | 1992-05-27 | 1997-02-25 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
US5643598A (en) * | 1988-03-09 | 1997-07-01 | Lvmh Recherche | Method of skin care utilizing liposomes containing Scutellaria extracts |
US5650432A (en) * | 1995-03-24 | 1997-07-22 | Jlb, Inc. | Method of treating or preventing non-viral microbial infection |
US5650433A (en) * | 1993-07-09 | 1997-07-22 | Kureha Chemical Industry Co., Ltd. | Chondroprotective agents |
US5651987A (en) * | 1991-12-17 | 1997-07-29 | Fuisz Technologies Ltd. | Ulcer prevention and treatment composition |
US5756538A (en) * | 1993-08-17 | 1998-05-26 | University Of Strathclyde | Flavonoid and biflavonoid derivatives, their pharmaceutical compositions, their anxiolytic activity |
US5773014A (en) * | 1996-10-07 | 1998-06-30 | Bioetica, Inc. | Compositions and methods for inhibiting the formation of unwanted skin pigmentation |
US5795911A (en) * | 1996-11-18 | 1998-08-18 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Composition for treating Condyloma acuminata |
US5858371A (en) * | 1997-02-05 | 1999-01-12 | Panacea Biotech Limited | Pharmaceutical composition for the control and treatment of anorectal and colonic diseases |
US5886029A (en) * | 1997-09-05 | 1999-03-23 | Dhaliwal; Kirpal S. | Method and composition for treatment of diabetes |
US5922756A (en) * | 1998-02-14 | 1999-07-13 | Chan; Marion Man-Ying | Method of inhibiting nitric oxide synthase |
US5962517A (en) * | 1997-01-31 | 1999-10-05 | Murad; Howard | Pharmaceutical compositions and methods for treating acne |
US5968973A (en) * | 1996-11-18 | 1999-10-19 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Method for treating hyperplasia |
US6083921A (en) * | 1998-01-12 | 2000-07-04 | Xu; Kai Jian | Pharmaceutical compositions and method of using same |
US6093403A (en) * | 1997-08-01 | 2000-07-25 | Phytocell Research, Inc. | Sugar imbalance and diabetes treating herbal formulation |
US6126950A (en) * | 1997-06-24 | 2000-10-03 | Council Of Scientific And Industrial Research | Composition useful for healing and protecting skin |
US6126940A (en) * | 1994-06-30 | 2000-10-03 | Kyowa Hakko Kogyo Co., Ltd. | Hair-growing agent comprised of proanthocyanidins |
US6197808B1 (en) * | 1996-11-18 | 2001-03-06 | Cancer Instititute (Hospital), Chinese Academy Of Medical Sciences | Methods for treating hyperplasia |
US6217875B1 (en) * | 1997-04-23 | 2001-04-17 | Oryza Oil & Fat Chemical Co., Ltd. | Inhibitors of lipoxygenase |
US6235294B1 (en) * | 1998-05-15 | 2001-05-22 | Coletica | Flavonoide esters and their use notably in cosmetics |
US6248341B1 (en) * | 2000-01-14 | 2001-06-19 | Color Access, Inc. | Method of treating topical angiogenesis-related disorders |
US6264995B1 (en) * | 1999-10-19 | 2001-07-24 | Thomas Newmark | Herbal composition for reducing inflammation and methods of using same |
US6290995B1 (en) * | 2000-02-08 | 2001-09-18 | Zhao Xinxian | Plant drug for preventing cancer II |
US6319523B1 (en) * | 2000-06-29 | 2001-11-20 | James H. Zhou | Composition and method for inhibiting oral bacteria |
US6387416B1 (en) * | 2001-04-05 | 2002-05-14 | Thomas Newmark | Anti-Inflammatory herbal composition and method of use |
US6391872B1 (en) * | 1997-11-04 | 2002-05-21 | Pfizer Inc | Indazole bioisostere replacement of catechol in therapeutically active compounds |
US20020086070A1 (en) * | 2000-03-11 | 2002-07-04 | Kuhrts Eric Hauser | Anti-inflammatory and connective tissue repair formulations |
US20020122836A1 (en) * | 2000-12-15 | 2002-09-05 | Pharmacia Corporation | Selective COX-2 inhibition from non-edible plant extracts |
US20020136784A1 (en) * | 2000-12-15 | 2002-09-26 | Pharmacia Corporation | Selective COX-2 inhibition from plant extracts |
US6475530B1 (en) * | 2000-05-31 | 2002-11-05 | Eric H. Kuhrts | Methods and compositions for producing weight loss |
US6555573B2 (en) * | 2000-12-21 | 2003-04-29 | The Quigley Corporation | Method and composition for the topical treatment of diabetic neuropathy |
US20030125264A1 (en) * | 2001-12-29 | 2003-07-03 | Kimberly-Clark Worldwide, Inc. | Methods For Treating Wounds |
US20030166583A1 (en) * | 2002-02-22 | 2003-09-04 | Oliver Yoa-Pu Hu | Dermal cytochrome P450 1A inhibitors and enhancers |
US20030170186A1 (en) * | 2000-04-18 | 2003-09-11 | Bernadette Geers | Novel flavone glycoside derivatives for use in cosmetics, pharmaceuticals and nutrition |
US20030232763A1 (en) * | 2002-04-30 | 2003-12-18 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
US6685971B2 (en) * | 2001-06-28 | 2004-02-03 | Rongxiang Xu | Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
US20050049206A1 (en) * | 2003-09-01 | 2005-03-03 | Gong Bang Qiang | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases |
US20060079467A1 (en) * | 2002-04-30 | 2006-04-13 | Unigen Pharmaceuticals, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
US7045158B2 (en) * | 2001-09-17 | 2006-05-16 | Wolfson Philip E | Standardized extracts of Scutellaria lateriflora |
US20060204596A1 (en) * | 2005-03-10 | 2006-09-14 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-Ring flavonoids and flavans as a therapeutic agent |
US7108868B2 (en) * | 2002-03-22 | 2006-09-19 | Unigen Pharmaceuticals, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
US7192611B2 (en) * | 2002-03-01 | 2007-03-20 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
US20070135359A1 (en) * | 2003-02-28 | 2007-06-14 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring Flavonoids as Potent COX-2 Inhibitors |
US20070264361A1 (en) * | 2004-09-01 | 2007-11-15 | Unigen, Inc. | Composition for Suppressing Cyclooxygenase and/or 5-Lypoxygenase |
US20080096826A1 (en) * | 2002-04-30 | 2008-04-24 | Unigen Pharmaceuticals, Inc. | Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans For Use In The Prevention And Treatment Of Cognitive Decline And Age-Related Memory Impairments |
US7531521B2 (en) * | 2003-02-26 | 2009-05-12 | Unigen Pharmaceuticals, Inc. | Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions |
US7615239B2 (en) * | 2002-04-15 | 2009-11-10 | Tetsuo Santo | Tea for treating dermatitis comprising herbal extracts |
Family Cites Families (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4035510A (en) * | 1976-09-15 | 1977-07-12 | Scott Eugene J Van | Treatment of acne utilizing N-methyldiethanolamine |
US4201776A (en) | 1977-01-31 | 1980-05-06 | The Green Cross Corporation | Food additive for reinforcing foods deficient in fiber content |
GB2024817B (en) | 1978-03-15 | 1982-09-22 | Wellcome Found | Flavan derivatives |
JPS5738721A (en) | 1980-08-20 | 1982-03-03 | Wataru Sakai | Production of bamboo extract having effect for hemorrhoids |
JPS57109720A (en) | 1980-12-22 | 1982-07-08 | Continentalfuaama | Medicine containing (+)-catechine and/or its salt for degenerated disease of articular gristle |
GB2115409B (en) | 1982-02-24 | 1985-08-07 | Zyma Sa | Novel crystal modifications of (+)-catechin |
JPS6150921A (ja) | 1984-08-20 | 1986-03-13 | Ichimaru Fuarukosu Kk | バイカリンの精製化法 |
JPS6183179A (ja) | 1984-09-28 | 1986-04-26 | Otsuka Pharmaceut Co Ltd | 新規フラボン誘導体 |
JPS61161219A (ja) | 1985-01-08 | 1986-07-21 | Osaka Chem Lab | アトピ−性皮膚炎症用化粧料組成物 |
JPS61238719A (ja) | 1985-04-17 | 1986-10-24 | Shiseido Co Ltd | 頭髪化粧料 |
US4627977A (en) | 1985-09-13 | 1986-12-09 | Colgate-Palmolive Company | Anticalculus oral composition |
JPS6327435A (ja) | 1986-07-18 | 1988-02-05 | Ichimaru Pharcos Co Ltd | バイカレイン高含有エキスの抽出法 |
US5156835A (en) | 1987-01-30 | 1992-10-20 | Colgate-Palmolive Company | Antibacterial antiplaque oral composition |
IN168400B (ko) | 1987-01-30 | 1991-03-23 | Colgate Palmolive Co | |
CA1308661C (en) | 1987-06-26 | 1992-10-13 | Masayasu Kurono | AGENT FOR INHIBITING BINDING OF 5.alpha.-DIHYDRO-TESTOSTERONE WITH ANDROGEN RECEPTOR AS WELL AS PROCESS FOR OBTAINING SAME |
US5098709A (en) | 1987-07-21 | 1992-03-24 | Kang Kwon J | Method of administrating a fused salt from natural substances, namely ginkgo, persimmon, pine, and bamboo in the treatment of inflammations |
JPH0662408B2 (ja) | 1987-10-01 | 1994-08-17 | 太陽化学株式会社 | 抗う蝕及び抗歯周病組成物 |
US5096714A (en) | 1988-06-28 | 1992-03-17 | Hauser-Kuhrts, Inc. | Prolonged release drug tablet formulations |
US4965067A (en) | 1988-08-10 | 1990-10-23 | The Proctor & Gamble Company | Oral compositions |
FR2651132B1 (fr) * | 1989-08-30 | 1993-01-08 | Pacific Chem Co Ltd | Agents de protection des cellules contre les especes chimiques a oxygene actif et leur preparation. |
JPH03240725A (ja) | 1990-02-15 | 1991-10-28 | Senjiyu Seiyaku Kk | メイラード反応阻害剤 |
JPH03251518A (ja) | 1990-02-26 | 1991-11-11 | Ichimaru Pharcos Co Ltd | 竹から抽出されたフケ菌発育阻害成分を含有する皮膚・頭皮・頭髪剤 |
CN1028604C (zh) | 1990-06-13 | 1995-05-31 | 成都中医学院 | 一种中药鲜竹沥的制备方法 |
US5585371A (en) | 1990-08-29 | 1996-12-17 | Humanetics Corporation | Treatment of immune system with Δ5-androstenes |
US5096701A (en) | 1990-12-18 | 1992-03-17 | The Procter & Gamble Company | Oral compositions |
JPH05271088A (ja) | 1991-12-27 | 1993-10-19 | Ruibosuteii Japan:Kk | 皮膚疾患・免疫反応による組織障害改善治療剤 |
FR2687572B1 (fr) * | 1992-02-26 | 1995-06-09 | Oreal | Utilisation de certains flavonouides dans des compositions cosmetiques, et procede de protection de la peau, ses phaneres et des compositions cosmetiques. |
JPH05331061A (ja) | 1992-06-01 | 1993-12-14 | Tsumura & Co | アポトーシス誘起剤 |
JPH05331161A (ja) | 1992-05-27 | 1993-12-14 | Tsumura & Co | クロモン誘導体及び該化合物を有効成分とするアルドー スリダクターゼ阻害剤 |
US5320830A (en) | 1992-12-30 | 1994-06-14 | The Procter & Gamble Company | Oral compositions |
JP3240725B2 (ja) | 1993-02-15 | 2001-12-25 | ソニー株式会社 | 配線構造とその製法 |
US5364845C1 (en) | 1993-03-31 | 2002-09-10 | Nutramax Lab Inc | Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue |
JPH0710768A (ja) | 1993-05-24 | 1995-01-13 | Suntory Ltd | マメ科植物抽出物を有効成分とするヒアルロニダーゼ阻害剤 |
CN1096680A (zh) | 1993-06-19 | 1994-12-28 | 金赞星 | 治疗脑血管病的药 |
JP3529811B2 (ja) | 1993-06-30 | 2004-05-24 | 三省製薬株式会社 | 皮膚外用剤 |
CN1093914A (zh) | 1993-07-04 | 1994-10-26 | 钟定铨 | 万应喉风散及其制造方法 |
JPH0755895A (ja) | 1993-08-10 | 1995-03-03 | Fujitsu Ltd | 高効率故障検出用テストパターンの作成方法 |
CN1101856A (zh) | 1993-10-20 | 1995-04-26 | 宋海 | 一种治疗烧、烫伤的中药烫可喷 |
JP3811198B2 (ja) | 1993-11-17 | 2006-08-16 | 株式会社創研 | 米からの抗アレルギー剤 |
JP3222672B2 (ja) | 1993-12-16 | 2001-10-29 | 三井農林株式会社 | タンパク質合成阻害剤 |
CN1043406C (zh) | 1993-12-27 | 1999-05-19 | 尚庆英 | 复方清带散的制备方法 |
JPH07223941A (ja) * | 1994-02-14 | 1995-08-22 | Nippon Ham Kk | 抗補体作用物質 |
JP3191549B2 (ja) | 1994-02-15 | 2001-07-23 | 松下電器産業株式会社 | 半導体メモリ装置 |
JPH07242555A (ja) | 1994-03-08 | 1995-09-19 | Suntory Ltd | グルコシルトランスフェラーゼ阻害剤およびこれを有効成分として含有する抗う蝕剤並びに抗う蝕性食品 |
JP2711630B2 (ja) | 1994-04-07 | 1998-02-10 | 株式会社大阪薬品研究所 | 皮膚外用剤 |
JPH0826969A (ja) | 1994-07-15 | 1996-01-30 | Osaka Yakuhin Kenkyusho:Kk | 化粧料組成物 |
KR960003725A (ko) | 1994-07-16 | 1996-02-23 | 신국현 | 황금의 후라보노이드 성분으로 된 백내장 치료제 |
JPH08104628A (ja) | 1994-10-04 | 1996-04-23 | Sumitomo Pharmaceut Co Ltd | マトリックスメタロプロテアーゼ阻害剤 |
KR960040370A (ko) | 1995-05-01 | 1996-12-17 | 강상모 | 알콜 장해 예방 및 치료제 조성물 |
US5589160A (en) | 1995-05-02 | 1996-12-31 | The Procter & Gamble Company | Dentifrice compositions |
CA2175985A1 (en) | 1995-05-10 | 1996-11-11 | Yoichi Kiyosuke | Pharmaceutical composition containing substance inhibiting hsp47 production |
JP3488325B2 (ja) | 1995-09-28 | 2004-01-19 | 株式会社大和生物研究所 | 笹茶及びその製造方法 |
GB2306321A (en) | 1995-10-24 | 1997-05-07 | Anne Child | The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders |
JPH09227374A (ja) | 1996-02-28 | 1997-09-02 | Taiyo Kagaku Co Ltd | ストレスタンパク質産生抑制組成物 |
EP2110134A1 (en) | 1996-04-02 | 2009-10-21 | Mars, Incorporated | Cocoa extract compounds and methods for making and using the same |
JPH09278662A (ja) | 1996-04-10 | 1997-10-28 | Nof Corp | 抗アレルギー剤 |
JPH1025238A (ja) | 1996-07-10 | 1998-01-27 | Mikimoto Pharmaceut Co Ltd | 皮膚外用剤 |
JPH10130162A (ja) | 1996-10-31 | 1998-05-19 | Kanebo Ltd | ヒアルロン酸分解阻害剤、ヒアルロン酸異常分解疾患治療剤および化粧料 |
US5817299A (en) | 1996-11-01 | 1998-10-06 | E-L Management Corp. | Non-chemical sunscreen composition |
JPH10167960A (ja) * | 1996-12-12 | 1998-06-23 | Les-Bell:Kk | 肝細胞ガン再発抑制剤 |
AT407057B (de) | 1996-12-19 | 2000-12-27 | Voest Alpine Schienen Gmbh | Profiliertes walzgut und verfahren zu dessen herstellung |
JPH10182415A (ja) | 1996-12-20 | 1998-07-07 | Rashieru Seiyaku Kk | 化粧料組成物 |
US5804168A (en) * | 1997-01-29 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for protecting and treating sun damaged skin |
CN1189365A (zh) | 1997-01-31 | 1998-08-05 | 雷学军 | 抗艾滋病病毒、梅毒螺旋体、淋菌、滴虫的药物 |
GB9704904D0 (en) | 1997-03-10 | 1997-04-30 | Riley Fletcher Foundation The | Essential oil composition |
US5766614A (en) | 1997-03-20 | 1998-06-16 | Yong; Liu | Burn treatment compositions containing herbal mix |
WO1998042363A1 (fr) | 1997-03-21 | 1998-10-01 | Shiseido Company, Ltd. | Immunostimulants |
JPH10287528A (ja) | 1997-04-07 | 1998-10-27 | Rashieru Seiyaku Kk | 化粧料組成物 |
PL187310B1 (pl) | 1997-04-29 | 2004-06-30 | Antoni Gwardys | Naturalny preparat przeciwutleniający |
US6319507B1 (en) * | 1997-05-02 | 2001-11-20 | Kobo Products, Inc. | Agar gel bead composition and method |
US5886155A (en) | 1997-06-18 | 1999-03-23 | Bioresources International Inc. | Purification of miraculin glycoprotein using tandem hydrophobic interaction chromatography |
KR19990015612A (ko) | 1997-08-07 | 1999-03-05 | 한영복 | 황백피와 마타리 식물의 혼합추출물을 함유하는 c형 간염 치료제조성물 |
CN1062753C (zh) | 1997-10-21 | 2001-03-07 | 陈新学 | 防治眼睛疾病的药物 |
JPH11140497A (ja) * | 1997-10-31 | 1999-05-25 | Amyuure:Kk | カテキン入り石鹸 |
EP1027045A4 (en) | 1997-10-31 | 2004-12-08 | Arch Dev Corp | METHODS AND COMPOSITIONS FOR REGULATING 5-ALPHA-REDUCTASE ACTIVITY |
US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
US6221341B1 (en) | 1997-11-19 | 2001-04-24 | Oraceutical Llc | Tooth whitening compositions |
CN1066055C (zh) | 1998-03-17 | 2001-05-23 | 浙江农业大学 | 从竹叶中提取黄酮类化合物浸膏或粉剂的生产方法 |
US5908628A (en) | 1998-05-01 | 1999-06-01 | Hou; Liping | Compositions with analgesic, antipyretic and antiinflammatory properties |
EP0956867A1 (de) | 1998-05-12 | 1999-11-17 | Franz-Peter Dr. Liebel | Verwendung von Flavonoidglykosiden, Gerbstoffen und Mikroorganismen zur Therapie und Prophylaxe des Diabetes mellitus |
JP2000044481A (ja) | 1998-07-30 | 2000-02-15 | Sunstar Inc | 皮膚外用剤 |
US6080401A (en) | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
JP4507027B2 (ja) | 1998-12-04 | 2010-07-21 | 明治乳業株式会社 | Mmp阻害剤 |
US6194469B1 (en) | 1998-12-11 | 2001-02-27 | Board Of Trustees Operating Michigan State Univeristy | Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids |
US20020098207A1 (en) | 1999-02-08 | 2002-07-25 | Daniel H. Maes | Cholesterol sulfate compositions for enhancement of stratum corneum function |
US6264926B1 (en) | 1999-02-12 | 2001-07-24 | Council Of Scientific And Industrial Research | Formulation useful as a natural herbal tooth powder |
US6241972B1 (en) | 1999-02-19 | 2001-06-05 | Block Drug Company, Inc. | Oral care formulation for the treatment of sensitivity teeth |
KR100317112B1 (ko) | 1999-03-18 | 2001-12-22 | 한영복 | 지모와 황백피의 혼합 수추출물을 포함하는 염증 및 통증 치료용조성물 및 그 제조 방법 |
WO2000059523A1 (en) | 1999-04-08 | 2000-10-12 | Metagenics, Inc. | Composition and method for treatment of inflammation and pain in mammals |
US6333304B1 (en) | 1999-04-20 | 2001-12-25 | Teresa K. Bath | Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue |
WO2000067749A1 (en) | 1999-05-05 | 2000-11-16 | Unilever N.V. | Food product |
JP4082823B2 (ja) * | 1999-05-06 | 2008-04-30 | 日本メナード化粧品株式会社 | 光毒性抑制剤 |
EP1207862A2 (en) | 1999-06-07 | 2002-05-29 | The University Of Sheffield | Arthritis treatment |
KR20010017481A (ko) | 1999-08-11 | 2001-03-05 | 신상국 | 여드름 제거용 음료 조성물 및 그 제조방법 |
CN1083492C (zh) | 1999-09-17 | 2002-04-24 | 哈尔滨工业大学 | 碳化锆颗粒增强钨复合材料的制备方法 |
JP2001187744A (ja) | 1999-10-19 | 2001-07-10 | Tasuku Okuda | 細胞活性化剤及びこれを用いた製品 |
AU7957000A (en) | 1999-10-25 | 2001-05-08 | Japan As Represented By Director General Of Agency Of National Cancer Center | Cyclooxygenase-2 expression inhibitors |
RU2186578C2 (ru) | 1999-10-26 | 2002-08-10 | Научно-исследовательский институт фармакологии Томского научного центра РАМН | Ноотропное и адаптогенное средство и пищевая добавка на его основе |
KR100390639B1 (ko) | 2000-01-12 | 2003-07-07 | 김미정 | 대나무 잎 추출물을 유효성분으로 첨가한 식품조성물의 제조방법 |
CN1107511C (zh) | 2000-01-24 | 2003-05-07 | 张俊锋 | 一种治疗感冒的药物 |
JP2001220353A (ja) | 2000-02-07 | 2001-08-14 | Noevir Co Ltd | ホスフォリパーゼa2阻害剤 |
KR100364383B1 (ko) | 2000-02-10 | 2002-12-18 | 김호철 | 신경보호작용을 갖는 황금추출물 및 이를 함유하는 약학적제제 |
EP1127572A3 (en) | 2000-02-25 | 2003-05-02 | Basf Aktiengesellschaft | Use of flavones for treating cycloxygenase-2 mediated diseases |
KR20020089440A (ko) | 2000-04-11 | 2002-11-29 | 다카라 바이오 가부시키가이샤 | 치료제 |
EP1147764A3 (en) * | 2000-04-19 | 2002-03-20 | Nof Corporation | Cosmetic composition |
JP4719372B2 (ja) | 2000-06-21 | 2011-07-06 | 花王株式会社 | Ppar依存的遺伝子転写活性化剤 |
KR100572408B1 (ko) | 2000-07-26 | 2006-04-19 | 가부시키가이샤 호오도 | 진양성 조성물 및 창상치유촉진 조성물 |
ATE325612T1 (de) | 2000-07-28 | 2006-06-15 | Immupharm Aps | Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen |
JP2002053484A (ja) | 2000-08-07 | 2002-02-19 | Asahi Breweries Ltd | リパーゼ阻害剤およびそれを含む飲食品 |
US6371872B1 (en) * | 2000-08-14 | 2002-04-16 | Westphal Daley | Lateral positioning and recycling table tennis robot |
KR100417791B1 (ko) | 2000-08-14 | 2004-02-11 | 미즈코리아 주식회사 | 항균 및 미용기능을 갖는 생약추출물과 이를 함유한 제품 |
CN1285202A (zh) | 2000-08-26 | 2001-02-28 | 田积天 | 火清正阳帖 |
ATE312464T1 (de) | 2000-09-22 | 2005-12-15 | Gen Instrument Corp | Sicherheitsarchitektur der internet-protokoll telefonie |
KR20020031608A (ko) | 2000-10-19 | 2002-05-03 | 이응세 | 항균효과가 우수한 황금 추출물, 그의 제조방법 및 그를포함하는 약학적 조성물 |
WO2002042429A2 (en) | 2000-11-03 | 2002-05-30 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
FR2816839B1 (fr) * | 2000-11-20 | 2003-09-26 | Schwartz Laboratoires Robert | Produit preparant et protegeant la peau contre les rayons uv, agissant a l'encontre du vieillissement cellulaire et excercant une action immunostimulante |
JP2004521880A (ja) | 2000-12-13 | 2004-07-22 | ユニバ−シティ オブ ロチェスタ− | 口腔組成物及びその使用方法 |
US20020146467A1 (en) | 2001-02-08 | 2002-10-10 | Jung Kyu Yong | Herbal composition for the prevention and treatment of dementia |
US6391346B1 (en) | 2001-04-05 | 2002-05-21 | Thomas Newmark | Anti-inflammatory, sleep-promoting herbal composition and method of use |
JP4901025B2 (ja) * | 2001-06-22 | 2012-03-21 | 株式会社ナリス化粧品 | エラスターゼ阻害剤 |
EP1411958A4 (en) | 2001-06-27 | 2009-07-08 | Unigen Pharmaceuticals Inc | METHOD OF GENERATING, SCREENING AND DEREPLYING LIBRARIES OF NATURAL PRODUCTS FOR DISCOVERING THERAPEUTIC AGENTS |
DE10133203A1 (de) * | 2001-07-07 | 2003-01-16 | Beiersdorf Ag | Catechine oder Extrakte von grünem Tee enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut |
CN1395383A (zh) | 2001-07-10 | 2003-02-05 | 颜森辉 | 智能型全方位专家管理系统 |
JP3529745B2 (ja) * | 2001-07-10 | 2004-05-24 | アルケア株式会社 | 排泄物収容装具 |
DE10139791A1 (de) | 2001-08-14 | 2003-02-27 | Beiersdorf Ag | Verwendung von Oroxylin A zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter und trockener Haut |
DE10139793A1 (de) * | 2001-08-14 | 2003-02-27 | Beiersdorf Ag | Verwendung von Wogonin zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter und trockener Haut |
US7338971B2 (en) | 2001-08-30 | 2008-03-04 | El-Naggar Mawaheb M | Treatment of inflammatory, cancer, and thrombosis disorders |
KR100486763B1 (ko) | 2001-09-07 | 2005-05-03 | 학교법인고려중앙학원 | 항산화 활성이 있는 맹종죽엽 추출물 및 그 제조방법 |
JP2003081746A (ja) | 2001-09-12 | 2003-03-19 | Pola Chem Ind Inc | メラノサイトのデンドライトの伸長抑制剤及びそれを含有する化粧料 |
US20040057908A1 (en) | 2001-12-13 | 2004-03-25 | Bowen William H. | Oral compositions and use thereof |
JP2003212786A (ja) | 2002-01-16 | 2003-07-30 | Univ Nihon | 竹の抽出成分を有効成分とする皮膚外用薬 |
JP2003212771A (ja) | 2002-01-23 | 2003-07-30 | Taiyo Kagaku Co Ltd | 抗ナイセリア菌組成物 |
US6964784B2 (en) | 2002-03-07 | 2005-11-15 | Optigenex, Inc. | Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals |
JP4332357B2 (ja) * | 2002-03-27 | 2009-09-16 | 株式会社日立産機システム | エネルギー回収装置の運転方法 |
US6884783B2 (en) | 2002-05-03 | 2005-04-26 | Unigen Pharmaceuticals, Inc. | 7-Hydroxy chromones as potent antioxidants |
MXPA02004426A (es) * | 2002-05-03 | 2004-09-10 | Lopez Ochoa Fernando | Muro panel termico estructural modificado y losa panel termico estructural modificado. |
DE10392881B4 (de) | 2002-07-01 | 2007-09-06 | Lightgage Inc. | Frequenzabtast-Interferometer mit diffus-reflektierender Referenzoberfläche |
CN1511549A (zh) | 2002-12-27 | 2004-07-14 | 张小丽 | 含有黄芩的抗肿瘤、抗炎症及肿瘤预防药物的组合物 |
JP2004244385A (ja) | 2003-02-14 | 2004-09-02 | Pigeon Corp | 防齲蝕性を有する乳幼児用の口腔内洗浄液 |
BRPI0408814A (pt) | 2003-03-27 | 2006-04-04 | Unigen Inc | composição farmacêutica, e, alimento para o cuidado da saúde |
AU2004228021B2 (en) | 2003-04-04 | 2010-09-02 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
WO2005020932A2 (en) | 2003-09-02 | 2005-03-10 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US20070065524A1 (en) | 2003-11-07 | 2007-03-22 | Oaky Natural Co., Ltd. | Pharmaceutical composition containing guaiacol derivatives and syringol derivatives extracted from natural plant vinegar |
KR100465113B1 (ko) | 2004-01-15 | 2005-01-14 | 주식회사 유니젠 | 대나무 추출물 또는 이로부터 분리된 트리신을 포함하는조성물 |
KR100522579B1 (ko) | 2004-04-30 | 2005-10-19 | (주) 한약마을 | 항스트레스 효과를 갖는 황금 및 오미자 혼합 추출물을함유하는 약학조성물 |
KR100720971B1 (ko) | 2004-06-11 | 2007-05-22 | 주식회사 유니젠 | 대나무 또는 대나무 추출물을 포함하는 안드로젠 효능성조성물 |
US20060008749A1 (en) | 2004-07-08 | 2006-01-12 | Frank Sobel | Method for manufacturing of a mask blank for EUV photolithography and mask blank |
TW200630102A (en) | 2004-10-19 | 2006-09-01 | Unigen Pharmaceuticals Inc | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
US20060140881A1 (en) | 2004-12-22 | 2006-06-29 | Guofeng Xu | Oral care compositions containing flavonoids and flavans |
US8895084B2 (en) | 2004-12-23 | 2014-11-25 | Colgate-Palmolive Company | Oral care composition containing extract of unoxidized Camellia |
KR100720973B1 (ko) | 2005-03-18 | 2007-05-22 | 주식회사 유니젠 | 천연물 유래 아이소오리엔틴을 포함하는 히스타민 억제용약학 조성물 |
CN1686187A (zh) | 2005-03-23 | 2005-10-26 | 贵阳高新瑞得科技开发有限公司 | 小儿清肺化痰泡腾颗粒及其制法 |
CN100499971C (zh) * | 2005-11-04 | 2009-06-10 | 群康科技(深圳)有限公司 | 平面显示器 |
KR100761248B1 (ko) | 2006-10-12 | 2007-10-04 | 주식회사 유니젠 | 대나무 및 황금 추출물을 유효성분으로 함유하는 아토피성피부염 치료를 위한 조성물 |
JP5331061B2 (ja) | 2010-06-03 | 2013-10-30 | パナソニック株式会社 | 部品実装方法、部品実装機 |
KR102478533B1 (ko) | 2012-05-29 | 2022-12-16 | 유니젠, 인크. | 체중 관리를 위한 조성물 및 방법 |
-
2004
- 2004-04-02 AU AU2004228021A patent/AU2004228021B2/en not_active Ceased
- 2004-04-02 CN CN2004800148963A patent/CN1798568B/zh not_active Expired - Lifetime
- 2004-04-02 US US10/817,330 patent/US20040220119A1/en not_active Abandoned
- 2004-04-02 BR BRPI0409179-5A patent/BRPI0409179A/pt not_active IP Right Cessation
- 2004-04-02 JP JP2006509660A patent/JP4769184B2/ja not_active Expired - Fee Related
- 2004-04-02 CA CA002521429A patent/CA2521429A1/en not_active Abandoned
- 2004-04-02 WO PCT/US2004/010279 patent/WO2004089392A1/en active Application Filing
- 2004-04-02 EP EP04758816A patent/EP1631304A4/en not_active Ceased
-
2005
- 2005-10-04 KR KR1020057018874A patent/KR101151322B1/ko active IP Right Grant
-
2011
- 2011-02-16 US US13/028,853 patent/US8790724B2/en not_active Expired - Lifetime
-
2014
- 2014-07-29 US US14/445,688 patent/US9622964B2/en active Active
Patent Citations (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3686872A (en) * | 1970-06-30 | 1972-08-29 | Anthony James Whitworth | Soil grouting process |
US3706581A (en) * | 1970-10-05 | 1972-12-19 | Borden Co | Soil grouting process and composition |
US4268517A (en) * | 1979-08-30 | 1981-05-19 | Continental Pharma | Pharmaceutical composition and therapeutical method for treating degenerative affections of the articular cartilage |
US4374824A (en) * | 1981-01-27 | 1983-02-22 | Krishan Dyal Mathur | Dentifrice |
US5443983A (en) * | 1986-08-08 | 1995-08-22 | Regents Of The University Of Minnesota | Method of culturing lymphocytes and method of treatment using such lymphocytes |
US5643598A (en) * | 1988-03-09 | 1997-07-01 | Lvmh Recherche | Method of skin care utilizing liposomes containing Scutellaria extracts |
US4946684A (en) * | 1989-06-20 | 1990-08-07 | American Home Products Corporation | Fast dissolving dosage forms |
US5470589A (en) * | 1990-04-25 | 1995-11-28 | Traditional Chinese Medicine Research Laboratory, Inc. | Hardening agent for affected tissues of the digestive system |
US5651987A (en) * | 1991-12-17 | 1997-07-29 | Fuisz Technologies Ltd. | Ulcer prevention and treatment composition |
US5605929A (en) * | 1992-05-27 | 1997-02-25 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
US5650433A (en) * | 1993-07-09 | 1997-07-22 | Kureha Chemical Industry Co., Ltd. | Chondroprotective agents |
US5756538A (en) * | 1993-08-17 | 1998-05-26 | University Of Strathclyde | Flavonoid and biflavonoid derivatives, their pharmaceutical compositions, their anxiolytic activity |
US6126940A (en) * | 1994-06-30 | 2000-10-03 | Kyowa Hakko Kogyo Co., Ltd. | Hair-growing agent comprised of proanthocyanidins |
US5545411A (en) * | 1994-12-16 | 1996-08-13 | Bristol-Myers Squibb Company | Method for lowering viscosity by use of gum acacia |
US5650432A (en) * | 1995-03-24 | 1997-07-22 | Jlb, Inc. | Method of treating or preventing non-viral microbial infection |
US5773014A (en) * | 1996-10-07 | 1998-06-30 | Bioetica, Inc. | Compositions and methods for inhibiting the formation of unwanted skin pigmentation |
US5968973A (en) * | 1996-11-18 | 1999-10-19 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Method for treating hyperplasia |
US6197808B1 (en) * | 1996-11-18 | 2001-03-06 | Cancer Instititute (Hospital), Chinese Academy Of Medical Sciences | Methods for treating hyperplasia |
US5795911A (en) * | 1996-11-18 | 1998-08-18 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Composition for treating Condyloma acuminata |
US5962517A (en) * | 1997-01-31 | 1999-10-05 | Murad; Howard | Pharmaceutical compositions and methods for treating acne |
US5858371A (en) * | 1997-02-05 | 1999-01-12 | Panacea Biotech Limited | Pharmaceutical composition for the control and treatment of anorectal and colonic diseases |
US6217875B1 (en) * | 1997-04-23 | 2001-04-17 | Oryza Oil & Fat Chemical Co., Ltd. | Inhibitors of lipoxygenase |
US6126950A (en) * | 1997-06-24 | 2000-10-03 | Council Of Scientific And Industrial Research | Composition useful for healing and protecting skin |
US6093403A (en) * | 1997-08-01 | 2000-07-25 | Phytocell Research, Inc. | Sugar imbalance and diabetes treating herbal formulation |
US5886029A (en) * | 1997-09-05 | 1999-03-23 | Dhaliwal; Kirpal S. | Method and composition for treatment of diabetes |
US6391872B1 (en) * | 1997-11-04 | 2002-05-21 | Pfizer Inc | Indazole bioisostere replacement of catechol in therapeutically active compounds |
US6083921A (en) * | 1998-01-12 | 2000-07-04 | Xu; Kai Jian | Pharmaceutical compositions and method of using same |
US5922756A (en) * | 1998-02-14 | 1999-07-13 | Chan; Marion Man-Ying | Method of inhibiting nitric oxide synthase |
US6235294B1 (en) * | 1998-05-15 | 2001-05-22 | Coletica | Flavonoide esters and their use notably in cosmetics |
US6264995B1 (en) * | 1999-10-19 | 2001-07-24 | Thomas Newmark | Herbal composition for reducing inflammation and methods of using same |
US6248341B1 (en) * | 2000-01-14 | 2001-06-19 | Color Access, Inc. | Method of treating topical angiogenesis-related disorders |
US6290995B1 (en) * | 2000-02-08 | 2001-09-18 | Zhao Xinxian | Plant drug for preventing cancer II |
US20020086070A1 (en) * | 2000-03-11 | 2002-07-04 | Kuhrts Eric Hauser | Anti-inflammatory and connective tissue repair formulations |
US20030170186A1 (en) * | 2000-04-18 | 2003-09-11 | Bernadette Geers | Novel flavone glycoside derivatives for use in cosmetics, pharmaceuticals and nutrition |
US6475530B1 (en) * | 2000-05-31 | 2002-11-05 | Eric H. Kuhrts | Methods and compositions for producing weight loss |
US6319523B1 (en) * | 2000-06-29 | 2001-11-20 | James H. Zhou | Composition and method for inhibiting oral bacteria |
US20020136784A1 (en) * | 2000-12-15 | 2002-09-26 | Pharmacia Corporation | Selective COX-2 inhibition from plant extracts |
US20020122836A1 (en) * | 2000-12-15 | 2002-09-05 | Pharmacia Corporation | Selective COX-2 inhibition from non-edible plant extracts |
US6555573B2 (en) * | 2000-12-21 | 2003-04-29 | The Quigley Corporation | Method and composition for the topical treatment of diabetic neuropathy |
US6387416B1 (en) * | 2001-04-05 | 2002-05-14 | Thomas Newmark | Anti-Inflammatory herbal composition and method of use |
US6685971B2 (en) * | 2001-06-28 | 2004-02-03 | Rongxiang Xu | Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
US7045158B2 (en) * | 2001-09-17 | 2006-05-16 | Wolfson Philip E | Standardized extracts of Scutellaria lateriflora |
US20030125264A1 (en) * | 2001-12-29 | 2003-07-03 | Kimberly-Clark Worldwide, Inc. | Methods For Treating Wounds |
US20030166583A1 (en) * | 2002-02-22 | 2003-09-04 | Oliver Yoa-Pu Hu | Dermal cytochrome P450 1A inhibitors and enhancers |
US7192611B2 (en) * | 2002-03-01 | 2007-03-20 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
US7108868B2 (en) * | 2002-03-22 | 2006-09-19 | Unigen Pharmaceuticals, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
US20060269627A1 (en) * | 2002-03-22 | 2006-11-30 | Unigen Pharmaceuticals, Inc. | Isolation of a Dual Cox-2 and 5-Lipoxygenase Inhibitor from Acacia |
US7615239B2 (en) * | 2002-04-15 | 2009-11-10 | Tetsuo Santo | Tea for treating dermatitis comprising herbal extracts |
US20080096826A1 (en) * | 2002-04-30 | 2008-04-24 | Unigen Pharmaceuticals, Inc. | Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans For Use In The Prevention And Treatment Of Cognitive Decline And Age-Related Memory Impairments |
US20060177528A1 (en) * | 2002-04-30 | 2006-08-10 | Unigen Pharmaceuticals, Inc. | Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans As A Therapeutic Agent |
US20030232763A1 (en) * | 2002-04-30 | 2003-12-18 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
US20060079467A1 (en) * | 2002-04-30 | 2006-04-13 | Unigen Pharmaceuticals, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
US20080096827A1 (en) * | 2002-04-30 | 2008-04-24 | Unigen Pharmaceuticals, Inc. | Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans For Use In The Prevention And Treatment Of Cognitive Decline And Age-Related Memory Impairments |
US7514469B2 (en) * | 2002-04-30 | 2009-04-07 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
US7531521B2 (en) * | 2003-02-26 | 2009-05-12 | Unigen Pharmaceuticals, Inc. | Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions |
US20070135359A1 (en) * | 2003-02-28 | 2007-06-14 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring Flavonoids as Potent COX-2 Inhibitors |
US20050049206A1 (en) * | 2003-09-01 | 2005-03-03 | Gong Bang Qiang | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases |
US20070264361A1 (en) * | 2004-09-01 | 2007-11-15 | Unigen, Inc. | Composition for Suppressing Cyclooxygenase and/or 5-Lypoxygenase |
US20060204596A1 (en) * | 2005-03-10 | 2006-09-14 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-Ring flavonoids and flavans as a therapeutic agent |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8568799B2 (en) | 2002-03-22 | 2013-10-29 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from acacia |
US9168242B2 (en) | 2002-03-22 | 2015-10-27 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipdxygenase inhibitor from Acacia |
US9370544B2 (en) | 2002-04-30 | 2016-06-21 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
US8945518B2 (en) | 2002-04-30 | 2015-02-03 | Unigen, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
US9849152B2 (en) | 2002-04-30 | 2017-12-26 | Unigen, Inc. | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
US9655940B2 (en) | 2002-04-30 | 2017-05-23 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
US20060079467A1 (en) * | 2002-04-30 | 2006-04-13 | Unigen Pharmaceuticals, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
US9622964B2 (en) | 2003-04-04 | 2017-04-18 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
US8790724B2 (en) | 2003-04-04 | 2014-07-29 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
EP1849467A4 (en) * | 2005-02-01 | 2008-08-20 | Shanghai Gloriayx Biopharmaceu | SYNERGIC PHARMACEUTICAL PREPARATION CONTAINING BAICALEIN AND BAICALIN AND INTENDED FOR INHIBITION OF A TUMOR |
EP1849467A1 (en) * | 2005-02-01 | 2007-10-31 | Shanghai Gloriayx Biopharmaceuticals Co., Ltd | The synergistically pharmaceutical composition of baicalein and baicalin for inhibiting tumor |
US20060204596A1 (en) * | 2005-03-10 | 2006-09-14 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-Ring flavonoids and flavans as a therapeutic agent |
US20060222671A1 (en) * | 2005-03-30 | 2006-10-05 | Astion Development A/S | Dermatological compositions and salts for the treatment of dermatological diseases |
US8771761B2 (en) | 2006-10-12 | 2014-07-08 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
US8247007B2 (en) | 2006-10-12 | 2012-08-21 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and Scutellaria |
US9623068B2 (en) | 2006-10-12 | 2017-04-18 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
US20100015257A1 (en) * | 2006-10-12 | 2010-01-21 | Unigen, Inc. | Composition For Treating Atopic Dermatitis Comprising Extracts Of Bamboo And Scutellaria |
US20090280200A1 (en) * | 2008-05-08 | 2009-11-12 | Industrial Technology Research Institute | Herbal extracts which induce immune cells to produce interferon and activate toll-like receptors |
US20110044920A1 (en) * | 2009-08-07 | 2011-02-24 | Mary Kay Inc. | Topical skin care formulations |
WO2011073961A1 (en) | 2009-12-15 | 2011-06-23 | Natura Cosmeticos S.A | Process for obtaining a standardised extract of quercetin and 3-0-methylquercetin from flowers of macela (achyrocline satureioides), and cosmetic and pharmaceutical compositions comprising said extract |
CN114129495A (zh) * | 2021-12-10 | 2022-03-04 | 北京安德普泰医疗科技有限公司 | 一种抗炎舒敏修护组合物及其制备方法和应用 |
DE202022106782U1 (de) | 2022-12-03 | 2022-12-19 | Mohammed Azeemuddin | Antiurolithiatische, antiosteoporotische, antidiabetische und entzündungshemmende Zusammensetzung eines Polykräuterextraktes |
Also Published As
Publication number | Publication date |
---|---|
CN1798568A (zh) | 2006-07-05 |
CN1798568B (zh) | 2011-05-11 |
BRPI0409179A (pt) | 2006-05-02 |
US20150140140A1 (en) | 2015-05-21 |
JP2006522150A (ja) | 2006-09-28 |
US20110207806A1 (en) | 2011-08-25 |
WO2004089392A1 (en) | 2004-10-21 |
EP1631304A1 (en) | 2006-03-08 |
AU2004228021B2 (en) | 2010-09-02 |
US8790724B2 (en) | 2014-07-29 |
AU2004228021A1 (en) | 2004-10-21 |
CA2521429A1 (en) | 2004-10-21 |
KR101151322B1 (ko) | 2012-06-08 |
US9622964B2 (en) | 2017-04-18 |
KR20050121239A (ko) | 2005-12-26 |
EP1631304A4 (en) | 2007-03-21 |
JP4769184B2 (ja) | 2011-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9622964B2 (en) | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care | |
US9849152B2 (en) | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent | |
US8568799B2 (en) | Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from acacia | |
US8945518B2 (en) | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIGEN PHARMACEUTICALS, INC., COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JIA, QI;REEL/FRAME:014772/0043 Effective date: 20040414 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: UNIGEN, INC., WASHINGTON Free format text: CHANGE OF NAME;ASSIGNOR:UNIGEN PHARMACEUTICALS, INC.;REEL/FRAME:027015/0720 Effective date: 20100420 |